Heinz-Josef Lenz, MD

Title(s)Professor of Medicine
SchoolKeck School of Medicine of Usc
AddressNOR 3456
Health Sciences Campus
Los Angeles CA 90089-9173
Phone+1 323 865 3967
vCardDownload vCard
    Other Positions
    Title(s)J. Terrence Lanni Chair in Gastrointestinal Cancer Research

    Title(s)Co-Director, USC Center for Molecular Pathway and Drug Discovery

    Title(s)Co-Director of the USC Norris Center for Cancer Drug Development


    Collapse Biography 
    Collapse Awards and Honors
    Conquer Cancer Foundation1994ASCO Young Investigator Award
    Conquer Cancer Foundation1995  - 1998ASCO Career Development Award
    STOP CANCERCareer Development Award
    USC2003Bob Chandler Courage Award
    2003 Annual Retreat on Cancer Research2003The Gallo Award
    The WunderGlo Foundation20121st Annual Cancer Warrior Award
    Western Society of Clinical Investigation2016Outstanding Investigator Award
    USC2021USC Mentoring Award for Postdoctoral Fellows

    Collapse Overview 
    Collapse Overview
    Heinz-Josef Lenz, M.D., FACP, is the Associate Director for Clinical Research and Co-Leader of the Gastrointestinal Cancers Program at the USC Norris Comprehensive Cancer Center. Dr. Lenz is Professor of Medicine and Preventive Medicine, Section Head of GI Oncology in the Division of Medical Oncology and Co-Director of the Colorectal Center at the Keck School of Medicine of the University of Southern California.

    Dr. Lenz received his medical degree from Johannes-Gutenberg Universität in Mainz, Germany, in 1985. He completed a residency in Hematology and Oncology at the University Hospital Tübingen in Germany, a clerkship in Oncology at George Washington University in Washington, DC, and a clerkship in Hematology at Beth Israel Hospital of Harvard Medical School in Boston, Massachusetts. He served subsequent fellowships in Biochemistry and Molecular Biology at the USC Norris Comprehensive Cancer Center.

    An active researcher, Dr. Lenz focuses on topics including the regulation of gene expression involved in drug resistance, patients at high risk of developing colorectal cancer, and determination of carcinogenesis, methods of early detection, and better surveillance of these cancers. He is a member of several professional societies, including the American Association for Cancer Research, the American Gastroenterology Association, and the National Society of Genetic Counselors. He also serves on the National Advisory Board of a number of professional organizations. Dr. Lenz is the author of numerous peer-reviewed publications and invited papers, reviews, and editorials. He also serves as Co-Chair of the GI Committee and Correlative Science Committee for SWOG. He is a member of the NCI Task Force for Gastroesophageal Cancer, the NCI Steering Committee and the NCI Translational Science Committee. In addition to having an NCI-funded laboratory, he was a recipient of the ASCO Young Investigator Award, the ASCO Career Development Award, and the STOP Cancer Career Development Award. He received in 2021 the USC Mentoring Award as well as highly cited researchers in the world. He has been select as influential leader by the LA Business Journal in 2021 and 2023.

    As Deputy Cancer Center Director for Research Programs and Co-Director for the Center for Cancer Drug Development, Dr. Lenz oversees the programmatic and clinical activities of the Gastrointestinal Cancers, Genitourinary Cancers, Women’s Cancers, and Leukemia and Lymphoma Programs.

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. q-Diffusion leverages the full dimensionality of gene coexpression in single-cell transcriptomics. Commun Biol. 2024 Apr 02; 7(1):400. Marmarelis MG, Littman R, Battaglin F, Niedzwiecki D, Venook A, Ambite JL, Galstyan A, Lenz HJ, Ver Steeg G. PMID: 38565955.
      View in: PubMed   Mentions: Translation:HumansCells
    2. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2024 Mar 13; 12(3). Lenz HJ, Parikh A, Spigel DR, Cohn AL, Yoshino T, Kochenderfer M, Elez E, Shao SH, Deming D, Holdridge R, Larson T, Chen E, Mahipal A, Ucar A, Cullen D, Baskin-Bey E, Kang T, Hammell AB, Yao J, Tabernero J. PMID: 38485190; PMCID: PMC10941175.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies. Res Sq. 2024 Mar 11. Yazdani A, Yazdani A, Mendez-Giraldez R, Pillonetto G, Samiei E, Hadi R, Lenz HJ, Venook A, Samiei A, Nixon A, Lucci J, Kopetz S, Bertagnolli M, Perou C, Innocenti F. PMID: 38559223; PMCID: PMC10980102.
      View in: PubMed   Mentions:
    4. HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405. J Clin Oncol. 2024 Mar 08; JCO2301507. Battaglin F, Ou FS, Qu X, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Ashouri K, Zemla TJ, Blanke CD, Venook AP, Kabbarah O, Lenz HJ, Innocenti F. PMID: 38457761.
      View in: PubMed   Mentions:    Fields:    
    5. Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers. Mol Ther Oncol. 2024 Mar 21; 32(1):200786. Lou E, Xiu J, Baca Y, Saeed A, Prakash A, Gholami S, Subramanian S, Starr TK, Fontana E, Pandey R, Lenz HJ, Shields AF, Nabhan C, Oberley M, Seeber A, El-Deiry W. PMID: 38596288; PMCID: PMC10963927.
      View in: PubMed   Mentions:
    6. Differential responses to immune checkpoint inhibitors are governed by diverse mismatch repair gene alterations. Clin Cancer Res. 2024 Feb 13. Khushman MM, Toboni MD, Xiu J, Manne U, Farrell A, Lou E, Shields AF, Philip PA, Salem ME, Abraham J, Spetzler D, Marshall J, Jayachandran P, Hall MJ, Lenz HJ, Sahin IH, Seeber A, Powell MA. PMID: 38350001.
      View in: PubMed   Mentions:    Fields:    
    7. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer. Eur J Cancer. 2024 Apr; 201:113914. Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou FS, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Goldberg RM, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Michael Korn W, Venook AP, Sunakawa Y, Lenz HJ. PMID: 38359495.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients. Int J Cancer. 2024 May 15; 154(10):1794-1801. Lee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, Gootjes E, Lenz HJ, Iqbal S, Jones P, Baylin S, Rami V, Ahuja N, El Khoueiry A, Azad NS. PMID: 38312102.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    9. Evidence for a causal link between intra-pancreatic fat deposition and pancreatic cancer: A prospective cohort and Mendelian randomization study. Cell Rep Med. 2024 Feb 20; 5(2):101391. Yamazaki H, Streicher SA, Wu L, Fukuhara S, Wagner R, Heni M, Grossman SR, Lenz HJ, Setiawan VW, Le Marchand L, Huang BZ. PMID: 38280379; PMCID: PMC10897551.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-line Treatment of KRAS-mutant Metastatic Colorectal Cancer: A Phase 1b Clinical Study. Clin Cancer Res. 2024 Jan 17. Ahn DH, Barzi A, Ridinger M, Samuëlsz E, Subramanian RA, Croucher PJP, Smeal T, Kabbinavar FF, Lenz HJ. PMID: 38231047.
      View in: PubMed   Mentions:    Fields:    
    11. CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value. J Immunother Cancer. 2024 01 11; 12(1). Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, Wang J, Ou FS, Innocenti F, Mumenthaler SM, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, Zhang W, Khoukaz T, Roussos Torres E, Seeber A, Abraham JP, Lou E, Philip PA, Weinberg BA, Shields AF, Goldberg RM, Marshall JL, Venook AP, Korn WM, Lenz HJ. PMID: 38212126; PMCID: PMC10806545.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. A revised nomenclature for the lemur family of protein kinases. Commun Biol. 2024 01 08; 7(1):57. Mórotz GM, Bradbury NA, Caluseriu O, Hisanaga SI, Miller CCJ, Swiatecka-Urban A, Lenz HJ, Moss SJ, Giamas G. PMID: 38191649; PMCID: PMC10774328.
      View in: PubMed   Mentions: Translation:AnimalsCells
    13. A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial. Cancer Res Commun. 2024 01 04; 4(1):28-37. Tabernero J, Yoshino T, Stintzing S, de Gramont A, Gibbs P, Jonker DJ, Nygren P, Papadimitriou C, Prager GW, Tell R, Lenz HJ. PMID: 38059497; PMCID: PMC10765772.
      View in: PubMed   Mentions: Translation:HumansCTClinical Trials
    14. Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer. Res Sq. 2023 Dec 28. Malla M, Kumar Deshkmukh S, Wu S, Samec T, Olevian D, Naili R, Bassel ER, Xiu J, Farrell A, Lenz HJ, Lou E, Goel S, Spetzler D, Goldberg RM, Hazlehurst L. PMID: 38234761; PMCID: PMC10793489.
      View in: PubMed   Mentions:
    15. The role of total neoadjuvant therapy in locally advanced rectal cancer: a survey of specialists attending the All-Ireland Colorectal Cancer Conference 2022 including lead investigators of OPRA, PRODIGE-23 and RAPIDO. Ir J Med Sci. 2023 Dec 23. O'Brien T, Hospers G, Conroy T, Lenz HJ, Smith JJ, Andrews E, O'Neill B, Leonard G. PMID: 38141097.
      View in: PubMed   Mentions:    Fields:    
    16. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy. Res Sq. 2023 Dec 15. Yazdani A, Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, Shen JPYC, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F. PMID: 38168324; PMCID: PMC10760223.
      View in: PubMed   Mentions:
    17. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations. J Clin Oncol. 2024 Feb 01; 42(4):399-409. Innocenti F, Mu W, Qu X, Ou FS, Kabbarah O, Blanke CD, Venook AP, Lenz HJ, Rashid NU. PMID: 37992266; PMCID: PMC10824387.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    18. Non-canonical MLL1 activity regulates centromeric phase separation and genome stability. Nat Cell Biol. 2023 Nov; 25(11):1637-1649. Sha L, Yang Z, An S, Yang W, Kim S, Oh H, Xu J, Yin J, Wang H, Lenz HJ, An W, Cho US, Dou Y. PMID: 37945831.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    19. Disparities among Black and Hispanic colorectal cancer patients: Findings from the California Cancer Registry. Cancer Med. 2023 11; 12(22):20976-20988. Mendez JS, Wang R, Liu L, Zhang J, Schmitt SL, Figueiredo J, Lenz HJ, Stern MC. PMID: 37909220; PMCID: PMC10709728.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170. Eur J Cancer. 2023 Nov; 194:113339. Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ. PMID: 37813779.
      View in: PubMed   Mentions:    Fields:    
    21. Integration of Patient-Derived Organoids and Organ-on-Chip Systems: Investigating Colorectal Cancer Invasion within the Mechanical and GABAergic Tumor Microenvironment. bioRxiv. 2023 Sep 17. Strelez C, Perez R, Chlystek JS, Cherry C, Yoon AY, Haliday B, Shah C, Ghaffarian K, Sun RX, Jiang H, Lau R, Schatz A, Lenz HJ, Katz JE, Mumenthaler SM. PMID: 37745376; PMCID: PMC10515884.
      View in: PubMed   Mentions:
    22. Sexual dysfunction among early-onset colorectal cancer survivors: Sex-specific correlates of sexual health discussions between patients and providers. Cancer Causes Control. 2024 Jan; 35(1):111-120. Stal J, Yi SY, Cohen-Cutler S, Gallagher P, Barzi A, Freyer DR, Kaslander JN, Anto-Ocrah M, Lenz HJ, Miller KA. PMID: 37597065; PMCID: PMC10764568.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system. NPJ Precis Oncol. 2023 Jul 03; 7(1):64. Zimmer K, Kocher F, Untergasser G, Kircher B, Amann A, Baca Y, Xiu J, Korn WM, Berger MD, Lenz HJ, Puccini A, Fontana E, Shields AF, Marshall JL, Hall M, El-Deiry WS, Hsiehchen D, Macarulla T, Tabernero J, Pichler R, Khushman M, Manne U, Lou E, Wolf D, Sokolova V, Schnaiter S, Zeimet AG, Gulhati P, Widmann G, Seeber A. PMID: 37400502; PMCID: PMC10317977.
      View in: PubMed   Mentions: 5  
    24. Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer. JCO Precis Oncol. 2023 07; 7:e2200422. Chowdhury S, Gupta R, Millstein J, Lin K, Haridas V, Zeineddine MA, Parseghian C, Lenz HJ, Kopetz S, Shen JP. PMID: 37487150; PMCID: PMC10581628.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor-Induced Thyroiditis. AACE Clin Case Rep. 2023 Sep-Oct; 9(5):162-165. Chen DH, Lenz HJ, Lechner MG, Angell TE. PMID: 37736314; PMCID: PMC10509378.
      View in: PubMed   Mentions:
    26. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023 05; 24(5):496-508. Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS, MOUNTAINEER investigators. PMID: 37142372.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    27. Genetic Evidence Causally Linking Pancreas Fat to Pancreatic Cancer: A Mendelian Randomization Study. medRxiv. 2023 Apr 26. Yamazaki H, Streicher SA, Wu L, Fukuhara S, Wagner R, Heni M, Grossman SR, Lenz HJ, Setiawan VW, Marchand LL, Huang BZ. PMID: 37163062; PMCID: PMC10168411.
      View in: PubMed   Mentions:
    28. Phosphorylation and stabilization of EZH2 by DCAF1/VprBP trigger aberrant gene silencing in colon cancer. Nat Commun. 2023 04 17; 14(1):2140. Ghate NB, Kim S, Shin Y, Kim J, Doche M, Valena S, Situ A, Kim S, Rhie SK, Lenz HJ, Ulmer TS, Mumenthaler SM, An W. PMID: 37069142; PMCID: PMC10110550.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    29. The influence of frailty on perioperative outcomes in patients undergoing surgical resection of liver metastases: a nationwide readmissions database study. Ann Gastroenterol. 2023 May-Jun; 36(3):333-339. Shahrestani S, Silverstein M, Nasrollahi T, Nasrollahi T, Maas M, Ugarte C, Kulkarni S, Lenz HJ, Genyk Y. PMID: 37144016; PMCID: PMC10152815.
      View in: PubMed   Mentions:
    30. Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Cancer Epidemiol Biomarkers Prev. 2023 04 03; 32(4):487-495. Schuster AL, Crossnohere NL, Bachini M, Blair CK, Carpten JD, Claus EB, Colditz GA, Ding L, Drake BF, Fields RC, Janeway KA, Kwan BM, Lenz HJ, Ma Q, Mishra SI, Paskett ED, Rebbeck TR, Ricker C, Stern MC, Sussman AL, Tiner JC, Trent JM, Verhaak RG, Wagle N, Willman C, Bridges JF, Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. PMID: 36791345; PMCID: PMC10068438.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. Nat Genet. 2023 Mar; 55(3):519-520. Fernandez-Rozadilla C, Timofeeva M, Chen Z, Law P, Thomas M, Schmit S, Díez-Obrero V, Hsu L, Fernandez-Tajes J, Palles C, Sherwood K, Briggs S, Svinti V, Donnelly K, Farrington S, Blackmur J, Vaughan-Shaw P, Shu XO, Long J, Cai Q, Guo X, Lu Y, Broderick P, Studd J, Huyghe J, Harrison T, Conti D, Dampier C, Devall M, Schumacher F, Melas M, Rennert G, Obón-Santacana M, Martín-Sánchez V, Moratalla-Navarro F, Oh JH, Kim J, Jee SH, Jung KJ, Kweon SS, Shin MH, Shin A, Ahn YO, Kim DH, Oze I, Wen W, Matsuo K, Matsuda K, Tanikawa C, Ren Z, Gao YT, Jia WH, Hopper J, Jenkins M, Win AK, Pai R, Figueiredo J, Haile R, Gallinger S, Woods M, Newcomb P, Duggan D, Cheadle J, Kaplan R, Maughan T, Kerr R, Kerr D, Kirac I, Böhm J, Mecklin LP, Jousilahti P, Knekt P, Aaltonen L, Rissanen H, Pukkala E, Eriksson J, Cajuso T, Hänninen U, Kondelin J, Palin K, Tanskanen T, Renkonen-Sinisalo L, Zanke B, Männistö S, Albanes D, Weinstein S, Ruiz-Narvaez E, Palmer J, Buchanan D, Platz E, Visvanathan K, Ulrich C, Siegel E, Brezina S, Gsur A, Campbell P, Chang-Claude J, Hoffmeister M, Brenner H, Slattery M, Potter J, Tsilidis K, Schulze M, Gunter M, Murphy N, Castells A, Castellví-Bel S, Moreira L, Arndt V, Shcherbina A, Stern M, Pardamean B, Bishop T, Giles G, Southey M, Idos G, McDonnell K, Abu-Ful Z, Greenson J, Shulman K, Lejbkowicz F, Offit K, Su YR, Steinfelder R, Keku T, van Guelpen B, Hudson T, Hampel H, Pearlman R, Berndt S, Hayes R, Martinez ME, Thomas S, Corley D, Pharoah P, Larsson S, Yen Y, Lenz HJ, White E, Li L, Doheny K, Pugh E, Shelford T, Chan A, Cruz-Correa M, Lindblom A, Hunter D, Joshi A, Schafmayer C, Scacheri P, Kundaje A, Nickerson D, Schoen R, Hampe J, Stadler Z, Vodicka P, Vodickova L, Vymetalkova V, Papadopoulos N, Edlund C, Gauderman W, Thomas D, Shibata D, Toland A, Markowitz S, Kim A, Chanock S, van Duijnhoven F, Feskens E, Sakoda L, Gago-Dominguez M, Wolk A, Naccarati A, Pardini B, FitzGerald L, Lee SC, Ogino S, Bien S, Kooperberg C, Li C, Lin Y, Prentice R, Qu C, Bézieau S, Tangen C, Mardis E, Yamaji T, Sawada N, Iwasaki M, Haiman C, Le Marchand L, Wu A, Qu C, McNeil C, Coetzee G, Hayward C, Deary I, Harris S, Theodoratou E, Reid S, Walker M, Ooi LY, Moreno V, Casey G, Gruber S, Tomlinson I, Zheng W, Dunlop M, Houlston R, Peters U. PMID: 36782065.
      View in: PubMed   Mentions:    Fields:    
    32. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial. Oncologist. 2023 02 08; 28(2):e124-e127. Spira A, Wertheim MS, Kim EJ, Tan B, Lenz HJ, Nikolinakos P, Rich PL, Jehl G, Machl A, Ito R, Gulley JL, Kopetz S. PMID: 36576431; PMCID: PMC9907041.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    33. Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials. EClinicalMedicine. 2023 Mar; 57:101827. Wang J, Millstein J, Yang Y, Stintzing S, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Mancao C, Cremolini C, Liu T, Heinemann V, Falcone A, Shen L, Lenz HJ. PMID: 36816347; PMCID: PMC9932345.
      View in: PubMed   Mentions:
    34. Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions. Oncogene. 2023 02; 42(9):627-637. Jayachandran P, Battaglin F, Strelez C, Lenz A, Algaze S, Soni S, Lo JH, Yang Y, Millstein J, Zhang W, Shih JC, Lu J, Mumenthaler SM, Spicer D, Neman J, Roussos Torres ET, Lenz HJ. PMID: 36650218; PMCID: PMC9957733.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Lancet Oncol. 2023 02; 24(2):151-161. Wang J, Xiu J, Farrell A, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Liu T, Oberley M, Spetzler D, Korn WM, Shen L, Lenz HJ. PMID: 36681091; PMCID: PMC10599647.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    36. Peritoneal metastases from primary appendiceal and colorectal carcinomas demonstrate distinct molecular identities on comprehensive tumor analysis. J Surg Oncol. 2023 Apr; 127(5):815-822. Fleming AM, Deschner BW, Williard FW, Drake JA, Vanderwalde A, Xiu J, Somer BG, Yakoub D, Tsao MW, Glazer ES, Dickson PV, Shibata D, Philip PA, Hwang JJ, Shields AF, Marshall JL, Korn WM, Lenz HJ, Deneve JL. PMID: 36629137.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. Patient Care Satisfaction and Emergency Room Utilization among Young Adult Colorectal Cancer Survivors during the SARS-CoV-2 Pandemic: Lessons Learned. J Clin Med. 2023 Jan 06; 12(2). Kagramanov D, Miller KA, Gallagher P, Freyer DR, Milam JE, Lenz HJ, Barzi A. PMID: 36675396; PMCID: PMC9862726.
      View in: PubMed   Mentions:
    38. Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle. Proc Natl Acad Sci U S A. 2023 01 10; 120(2):e2214829120. Qu M, Zhang G, Qu H, Vu A, Wu R, Tsukamoto H, Jia Z, Huang W, Lenz HJ, Rich JN, Kay SA. PMID: 36595671; PMCID: PMC9926257.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    39. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. Nat Genet. 2023 01; 55(1):89-99. Fernandez-Rozadilla C, Timofeeva M, Chen Z, Law P, Thomas M, Schmit S, Díez-Obrero V, Hsu L, Fernandez-Tajes J, Palles C, Sherwood K, Briggs S, Svinti V, Donnelly K, Farrington S, Blackmur J, Vaughan-Shaw P, Shu XO, Long J, Cai Q, Guo X, Lu Y, Broderick P, Studd J, Huyghe J, Harrison T, Conti D, Dampier C, Devall M, Schumacher F, Melas M, Rennert G, Obón-Santacana M, Martín-Sánchez V, Moratalla-Navarro F, Oh JH, Kim J, Jee SH, Jung KJ, Kweon SS, Shin MH, Shin A, Ahn YO, Kim DH, Oze I, Wen W, Matsuo K, Matsuda K, Tanikawa C, Ren Z, Gao YT, Jia WH, Hopper J, Jenkins M, Win AK, Pai R, Figueiredo J, Haile R, Gallinger S, Woods M, Newcomb P, Duggan D, Cheadle J, Kaplan R, Maughan T, Kerr R, Kerr D, Kirac I, Böhm J, Mecklin LP, Jousilahti P, Knekt P, Aaltonen L, Rissanen H, Pukkala E, Eriksson J, Cajuso T, Hänninen U, Kondelin J, Palin K, Tanskanen T, Renkonen-Sinisalo L, Zanke B, Männistö S, Albanes D, Weinstein S, Ruiz-Narvaez E, Palmer J, Buchanan D, Platz E, Visvanathan K, Ulrich C, Siegel E, Brezina S, Gsur A, Campbell P, Chang-Claude J, Hoffmeister M, Brenner H, Slattery M, Potter J, Tsilidis K, Schulze M, Gunter M, Murphy N, Castells A, Castellví-Bel S, Moreira L, Arndt V, Shcherbina A, Stern M, Pardamean B, Bishop T, Giles G, Southey M, Idos G, McDonnell K, Abu-Ful Z, Greenson J, Shulman K, Lejbkowicz F, Offit K, Su YR, Steinfelder R, Keku T, van Guelpen B, Hudson T, Hampel H, Pearlman R, Berndt S, Hayes R, Martinez ME, Thomas S, Corley D, Pharoah P, Larsson S, Yen Y, Lenz HJ, White E, Li L, Doheny K, Pugh E, Shelford T, Chan A, Cruz-Correa M, Lindblom A, Hunter D, Joshi A, Schafmayer C, Scacheri P, Kundaje A, Nickerson D, Schoen R, Hampe J, Stadler Z, Vodicka P, Vodickova L, Vymetalkova V, Papadopoulos N, Edlund C, Gauderman W, Thomas D, Shibata D, Toland A, Markowitz S, Kim A, Chanock S, van Duijnhoven F, Feskens E, Sakoda L, Gago-Dominguez M, Wolk A, Naccarati A, Pardini B, FitzGerald L, Lee SC, Ogino S, Bien S, Kooperberg C, Li C, Lin Y, Prentice R, Qu C, Bézieau S, Tangen C, Mardis E, Yamaji T, Sawada N, Iwasaki M, Haiman C, Le Marchand L, Wu A, Qu C, McNeil C, Coetzee G, Hayward C, Deary I, Harris S, Theodoratou E, Reid S, Walker M, Ooi LY, Moreno V, Casey G, Gruber S, Tomlinson I, Zheng W, Dunlop M, Houlston R, Peters U. PMID: 36539618; PMCID: PMC10094749.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    40. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. Clin Cancer Res. 2022 11 14; 28(22):4957-4967. Kocher F, Puccini A, Untergasser G, Martowicz A, Zimmer K, Pircher A, Baca Y, Xiu J, Haybaeck J, Tymoszuk P, Goldberg RM, Petrillo A, Shields AF, Salem ME, Marshall JL, Hall M, Korn WM, Nabhan C, Battaglin F, Lenz HJ, Lou E, Choo SP, Toh CK, Gasteiger S, Pichler R, Wolf D, Seeber A. PMID: 36112544; PMCID: PMC9660543.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    41. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. Eur J Cancer. 2023 01; 178:162-170. Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ. PMID: 36446161.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment. Oncogene. 2022 10; 41(43):4769-4778. Battaglin F, Jayachandran P, Strelez C, Lenz A, Algaze S, Soni S, Lo JH, Yang Y, Millstein J, Zhang W, Roussos Torres ET, Shih JC, Mumenthaler SM, Neman J, Lenz HJ. PMID: 36182970; PMCID: PMC10591256.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    43. ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nat Commun. 2022 09 19; 13(1):5478. Johnson RM, Qu X, Lin CF, Huw LY, Venkatanarayan A, Sokol E, Ou FS, Ihuegbu N, Zill OA, Kabbarah O, Wang L, Bourgon R, de Sousa E Melo F, Bolen C, Daemen A, Venook AP, Innocenti F, Lenz HJ, Bais C. PMID: 36117191; PMCID: PMC9482920.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    44. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma. Cancer Lett. 2022 11 01; 548:215899. Zhang L, Li HT, Shereda R, Lu Q, Weisenberger DJ, O'Connell C, Machida K, An W, Lenz HJ, El-Khoueiry A, Jones PA, Liu M, Liang G. PMID: 36087682; PMCID: PMC9563073.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    45. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). J Clin Oncol. 2023 01 20; 41(3):472-478. Raghav K, Ou FS, Venook AP, Innocenti F, Sun R, Lenz HJ, Kopetz S. PMID: 36067452; PMCID: PMC9870237.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    46. Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations. Cancers (Basel). 2022 Sep 01; 14(17). Kurzrock R, Aggarwal C, Weipert C, Kiedrowski L, Riess J, Lenz HJ, Gandara D. PMID: 36077815; PMCID: PMC9454642.
      View in: PubMed   Mentions: 2  
    47. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405. Int J Cancer. 2023 01 15; 152(2):123-136. Van Blarigan EL, Ma C, Ou FS, Bainter TM, Venook AP, Ng K, Niedzwiecki D, Giovannucci E, Lenz HJ, Polite BN, Hochster HS, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Ciombor KK, Meyerhardt JA. PMID: 35904874; PMCID: PMC9691576.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    48. Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates. Oncologist. 2022 07 05; 27(7):579-586. Stal J, Yi SY, Cohen-Cutler S, Gallagher P, Barzi A, Freyer DR, Milam JE, Lenz HJ, Miller KA. PMID: 35427410; PMCID: PMC9255970.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    49. Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). Clin Cancer Res. 2022 07 01; 28(13):2779-2788. Nixon AB, Sibley AB, Liu Y, Hatch AJ, Jiang C, Mulkey F, Starr MD, Brady JC, Niedzwiecki D, Venook AP, Baez-Diaz L, Lenz HJ, O'Neil BH, Innocenti F, Meyerhardt JA, O'Reilly EM, Owzar K, Hurwitz HI. PMID: 34965954; PMCID: PMC9240111.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    50. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022 10; 33(10):1052-1060. André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Abdullaev S, Memaj A, Lei M, Dixon M, Kopetz S, Overman MJ. PMID: 35764271.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    51. Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes. Mol Ther. 2022 09 07; 30(9):3066-3077. Cheng Q, Dai Z, Smbatyan G, Epstein AL, Lenz HJ, Zhang Y. PMID: 35746867; PMCID: PMC9481992.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    52. Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. Eur J Cancer. 2022 09; 172:22-30. Wang J, Xiao Y, Loupakis F, Stintzing S, Yang Y, Arai H, Battaglin F, Kawanishi N, Jayachandran P, Soni S, Zhang W, Mancao C, Cremolini C, Liu T, Heinemann V, Falcone A, Shen L, Millstein J, Lenz HJ. PMID: 35749909.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    53. fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing. Bioinform Adv. 2022; 2(1):vbac047. Millstein J, Battaglin F, Arai H, Zhang W, Jayachandran P, Soni S, Parikh AR, Mancao C, Lenz HJ. PMID: 35747247; PMCID: PMC9210923.
      View in: PubMed   Mentions: 4  
    54. Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11). ESMO Open. 2022 06; 7(3):100512. Sunakawa Y, Satake H, Usher J, Jaimes Y, Miyamoto Y, Nakamura M, Kataoka M, Shiozawa M, Takagane A, Terazawa T, Watanabe T, Ishiguro K, Tanaka C, Takeuchi M, Fujii M, Danenberg K, Danenberg PV, Lenz HJ, Sekikawa T, Ichikawa W. PMID: 35688061; PMCID: PMC9271512.
      View in: PubMed   Mentions: 3  Translation:HumansCTClinical Trials
    55. Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? Br J Cancer. 2022 09; 127(5):957-967. Moretto R, Elliott A, Rossini D, Intini R, Conca V, Pietrantonio F, Sartore-Bianchi A, Antoniotti C, Rasola C, Scartozzi M, Salati M, Pella N, Calegari MA, Carullo M, Corti F, Mauri G, Fassan M, Masi G, Brodskiy P, Lenz HJ, Shields A, Lonardi S, Korn M, Cremolini C. PMID: 35665778; PMCID: PMC9428147.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    56. Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. Oncogene. 2022 06; 41(26):3455-3460. Puccini A, Poorman K, Catalano F, Seeber A, Goldberg RM, Salem ME, Shields AF, Berger MD, Battaglin F, Tokunaga R, Naseem M, Zhang W, Philip PA, Marshall JL, Korn WM, Lenz HJ. PMID: 35618879; PMCID: PMC9457205.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    57. Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial. Clin Colorectal Cancer. 2022 09; 21(3):259-266. Arai H, Millstein J, Yang Y, Stintzing S, Wang J, Battaglin F, Kawanishi N, Jayachandran P, Soni S, Zhang W, Heinemann V, Lenz HJ. PMID: 35710481.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    58. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. Clin Cancer Res. 2022 05 02; 28(9):1863-1870. Seeber A, Battaglin F, Zimmer K, Kocher F, Baca Y, Xiu J, Spizzo G, Novotny-Diermayr V, Rieder D, Puccini A, Swensen J, Ellis M, Goldberg RM, Grothey A, Shields AF, Marshall JL, Weinberg BA, Sackstein PE, Lim KH, Tan GS, Nabhan C, Korn WM, Amann A, Trajanoski Z, Berger MD, Lou E, Wolf D, Lenz HJ. PMID: 35254413; PMCID: PMC9064897.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    59. Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. Clin Cancer Res. 2022 04 14; 28(8):1690-1700. Innocenti F, Yazdani A, Rashid N, Qu X, Ou FS, Van Buren S, Bertagnolli MM, Kabbarah O, Blanke CD, Venook AP, Lenz HJ, Vincent BG. PMID: 35176136; PMCID: PMC9093780.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    60. Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Natl Cancer Inst. 2022 03 08; 114(3):427-435. Lipsyc-Sharf M, Zhang S, Ou FS, Ma C, McCleary NJ, Niedzwiecki D, Chang IW, Lenz HJ, Blanke CD, Piawah S, Van Loon K, Bainter TM, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg R, O'Reilly EM, Meyerhardt JA, Ng K. PMID: 34636852; PMCID: PMC8902338.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    61. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. J Natl Cancer Inst. 2022 02 07; 114(2):271-279. Moretto R, Elliott A, Zhang J, Arai H, Germani MM, Conca V, Xiu J, Stafford P, Oberley M, Abraham J, Spetzler D, Rossini D, Antoniotti C, Marshall J, Shields A, Lopes G, Lonardi S, Pietrantonio F, Tomasello G, Passardi A, Tamburini E, Santini D, Aprile G, Masi G, Falcone A, Lenz HJ, Korn M, Cremolini C. PMID: 34469533; PMCID: PMC8826505.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    62. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 02 01; 5(2):e2149040. Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, Bekaii-Saab T. PMID: 35179586; PMCID: PMC8857687.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    63. Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. J Geriatr Oncol. 2022 05; 13(4):469-479. McCleary NJ, Zhang S, Ma C, Ou FS, Bainter TM, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. PMID: 35105521; PMCID: PMC9058225.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    64. Prognostic utility of self-reported sarcopenia (SARC-F) in the Multiethnic Cohort. J Cachexia Sarcopenia Muscle. 2022 04; 13(2):987-1002. Wu AH, Setiawan VW, Lim U, Tseng CC, White KK, Shepherd J, Lenz HJ, Cheng I, Stram DO, Haiman C, Wilkens LR, Le Marchand L. PMID: 35098697; PMCID: PMC8977971.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    65. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. Eur J Cancer. 2022 03; 163:1-15. Papamichael D, Lopes GS, Olswold CL, Douillard JY, Adams RA, Maughan TS, Van Cutsem E, Venook AP, Lenz HJ, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, De Gramont A, Shi Q. PMID: 35033994.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    66. Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response. Front Oncol. 2021; 11:771173. Spiller ER, Ung N, Kim S, Patsch K, Lau R, Strelez C, Doshi C, Choung S, Choi B, Juarez Rosales EF, Lenz HJ, Matasci N, Mumenthaler SM. PMID: 34993134; PMCID: PMC8724556.
      View in: PubMed   Mentions: 7  
    67. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. J Natl Cancer Inst. 2021 11 29; 113(12):1705-1713. Yin J, Cohen R, Jin Z, Liu H, Pederson L, Adams R, Grothey A, Maughan TS, Venook A, Van Cutsem E, Punt C, Koopman M, Falcone A, Tebbutt NC, Seymour MT, Bokemeyer C, Rubio ED, Kaplan R, Heinemann V, Chibaudel B, Yoshino T, Zalcberg J, Andre T, De Gramont A, Shi Q, Lenz HJ. PMID: 34061178.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    68. Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Rep. 2021 Nov 16; 37(7):110033. Erbe R, Wang Z, Wu S, Xiu J, Zaidi N, La J, Tuck D, Fillmore N, Giraldo NA, Topper M, Baylin S, Lippman M, Isaacs C, Basho R, Serebriiskii I, Lenz HJ, Astsaturov I, Marshall J, Taverna J, Lee J, Jaffee EM, Roussos Torres ET, Weeraratna A, Easwaran H, Fertig EJ. PMID: 34788629.
      View in: PubMed   Mentions: 2     Fields:    
    69. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene. 2022 01; 41(2):260-267. Arai H, Elliott A, Millstein J, Xiu J, Ou FS, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanishi N, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Lockhart AC, Shields AF, Abraham JP, Magee D, Stafford P, Zhang J, Venook AP, Korn WM, Lenz HJ. PMID: 34728807; PMCID: PMC8738154.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. Mol Cancer Ther. 2022 01; 21(1):227-236. Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Baca Y, Hwang JJ, Marshall JL, VanderWalde AM, Shields AF, Lenz HJ, Korn WM, Salem M, Philip PA, Goldberg RM, Zeng J, Kim SS. PMID: 34725190; PMCID: PMC9506445.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    71. Reprogramming CBX8-PRC1 function with a positive allosteric modulator. Cell Chem Biol. 2022 04 21; 29(4):555-571.e11. Suh JL, Bsteh D, Hart B, Si Y, Weaver TM, Pribitzer C, Lau R, Soni S, Ogana H, Rectenwald JM, Norris JL, Cholensky SH, Sagum C, Umana JD, Li D, Hardy B, Bedford MT, Mumenthaler SM, Lenz HJ, Kim YM, Wang GG, Pearce KH, James LI, Kireev DB, Musselman CA, Frye SV, Bell O. PMID: 34715055; PMCID: PMC9035045.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    72. Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. NPJ Precis Oncol. 2021 Oct 27; 5(1):95. Puccini A, Seeber A, Xiu J, Goldberg RM, Soldato D, Grothey A, Shields AF, Salem ME, Battaglin F, Berger MD, El-Deiry WS, Tokunaga R, Naseem M, Zhang W, Arora SP, Khushman MM, Hall MJ, Philip PA, Marshall JL, Korn WM, Lenz HJ. PMID: 34707195; PMCID: PMC8551277.
      View in: PubMed   Mentions: 6  
    73. Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer. Br J Cancer. 2022 01; 126(1):72-78. Arai H, Xiao Y, Millstein J, Wang J, Battaglin F, Kawanishi N, Jayachandran P, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Parikh AR, Lenz HJ. PMID: 34689170; PMCID: PMC8727586.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    74. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022 01 10; 40(2):161-170. Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S. PMID: 34637336.
      View in: PubMed   Mentions: 180     Fields:    Translation:HumansCellsCTClinical Trials
    75. Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. Int J Cancer. 2022 01 15; 150(2):279-289. Quintanilha JCF, Wang J, Sibley AB, Xu W, Espin-Garcia O, Jiang C, Etheridge AS, Ratain MJ, Lenz HJ, Bertagnolli M, Kindler HL, Dickler MN, Venook A, Liu G, Owzar K, Lin D, Innocenti F. PMID: 34528705; PMCID: PMC8627468.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    76. BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. J Natl Cancer Inst. 2021 10 01; 113(10):1386-1395. Cohen R, Liu H, Fiskum J, Adams R, Chibaudel B, Maughan TS, Van Cutsem E, Venook A, Douillard JY, Heinemann V, Ja Punt C, Falcone A, Bokemeyer C, Kaplan R, Lenz HJ, Koopman M, Yoshino T, Zalcberg J, Grothey A, de Gramont A, Shi Q, André T. PMID: 33734401.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    77. Molecular characterization of squamous cell carcinoma of the anal canal. J Gastrointest Oncol. 2021 Oct; 12(5):2423-2437. Armstrong SA, Malley R, Wang H, Lenz HJ, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Hwang JJ, Philip PA, Shields AF, Marshall JL, Salem ME, Weinberg BA. PMID: 34790403; PMCID: PMC8576238.
      View in: PubMed   Mentions: 6  
    78. Clinical Significance of Circulating Tumor Cell Induced Epithelial-Mesenchymal Transition in Patients with Metastatic Colorectal Cancer by Single-Cell RNA-Sequencing. Cancers (Basel). 2021 Sep 28; 13(19). Kozuka M, Battaglin F, Jayachandran P, Wang J, Arai H, Soni S, Zhang W, Hirai M, Matsusaka S, Lenz HJ. PMID: 34638346; PMCID: PMC8507666.
      View in: PubMed   Mentions: 5  
    79. Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Rep. 2021 08 24; 36(8):109599. Erbe R, Wang Z, Wu S, Xiu J, Zaidi N, La J, Tuck D, Fillmore N, Giraldo NA, Topper M, Baylin S, Lippman M, Isaacs C, Basho R, Serebriiskii I, Lenz HJ, Astsaturov I, Marshall J, Taverna J, Lee J, Jaffee EM, Roussos Torres ET, Weeraratna A, Easwaran H, Fertig EJ. PMID: 34433020; PMCID: PMC8757482.
      View in: PubMed   Mentions: 10     Fields:    
    80. Time from Diagnosis and Correlates of Health-Related Quality of Life among Young Adult Colorectal Cancer Survivors. Cancers (Basel). 2021 Aug 11; 13(16). Miller KA, Stal J, Gallagher P, Weng Z, Freyer DR, Kaslander JN, Marin P, Lenz HJ, Milam JE, Govaerts L, Barzi A. PMID: 34439198; PMCID: PMC8392733.
      View in: PubMed   Mentions: 8  
    81. Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). Cancer. 2021 10 15; 127(20):3801-3808. Snyder RA, He J, Le-Rademacher J, Ou FS, Dodge AB, Zemla TJ, Paskett ED, Chang GJ, Innocenti F, Blanke C, Lenz HJ, Polite BN, Venook AP. PMID: 34374082; PMCID: PMC8478698.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    82. VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer. Mol Oncol. 2021 10; 15(10):2801-2817. Ghate NB, Kim S, Spiller E, Kim S, Shin Y, Rhie SK, Smbatyan G, Lenz HJ, Mumenthaler SM, An W. PMID: 34312968; PMCID: PMC8486565.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    83. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Eur J Cancer. 2021 09; 155:73-84. Antoniotti C, Korn WM, Marmorino F, Rossini D, Lonardi S, Masi G, Randon G, Conca V, Boccaccino A, Tomasello G, Passardi A, Swensen J, Ugolini C, Oberley M, Tamburini E, Casagrande M, Domenyuk V, Fontanini G, Giordano M, Abraham J, Spetzler D, Falcone A, Lenz HJ, Cremolini C. PMID: 34365081.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    84. Microsatellite Stable Colorectal Liver Metastases-Understanding the Mechanisms of Immune Resistance. JAMA Netw Open. 2021 08 02; 4(8):e2119025. Gholami S, Grothey A, Lenz HJ. PMID: 34369996.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    85. Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy. J Control Release. 2021 08 10; 336:433-442. Dai Z, Zhang XN, Cheng Q, Fei F, Hou T, Li J, Abdolvahabi A, Watanabe J, Pei H, Smbatyan G, Xie J, Lenz HJ, Louie SG, Zhang Y. PMID: 34197861; PMCID: PMC8373670.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    86. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene. 2021 07; 40(30):4894-4905. Wang J, Xiu J, Baca Y, Battaglin F, Arai H, Kawanishi N, Soni S, Zhang W, Millstein J, Salhia B, Goldberg RM, Philip PA, Seeber A, Hwang JJ, Shields AF, Marshall JL, Astsaturov I, Craig Lockhart A, Gatalica Z, Michael Korn W, Lenz HJ. PMID: 34163031.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    87. Impacts of the SARS-CoV-2 Pandemic on Young Adult Colorectal Cancer Survivors. J Adolesc Young Adult Oncol. 2022 04; 11(2):229-233. Miller KA, Kagramanov D, Cohen-Cutler S, Nadim B, Weng Z, Gallagher P, Kaslander JN, Freyer DR, Barzi A, Lenz HJ. PMID: 34143664; PMCID: PMC9057897.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    88. Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. Sci Rep. 2021 06 09; 11(1):12191. Naseem M, Cao S, Yang D, Millstein J, Puccini A, Loupakis F, Stintzing S, Cremolini C, Tokunaga R, Battaglin F, Soni S, Berger MD, Barzi A, Zhang W, Falcone A, Heinemann V, Lenz HJ. PMID: 34108518; PMCID: PMC8190302.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    89. Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS. Cells. 2021 05 21; 10(6). Lou E, Xiu J, Baca Y, Nelson AC, Weinberg BA, Beg MS, Salem ME, Lenz HJ, Philip P, El-Deiry WS, Korn WM. PMID: 34063999; PMCID: PMC8224072.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    90. Human colorectal cancer-on-chip model to study the microenvironmental influence on early metastatic spread. iScience. 2021 May 21; 24(5):102509. Strelez C, Chilakala S, Ghaffarian K, Lau R, Spiller E, Ung N, Hixon D, Yoon AY, Sun RX, Lenz HJ, Katz JE, Mumenthaler SM. PMID: 34113836; PMCID: PMC8169959.
      View in: PubMed   Mentions: 19  
    91. Correction to: KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. Oncogene. 2021 May; 40(19):3473. Stebbing J, Zhang H, Xu Y, Lit LC, Green AR, Grothey A, Lombardo Y, Periyasamy M, Blighe K, Zhang W, Shaw JA, Ellis IO, Lenz HJ, Giamas G. PMID: 33888869.
      View in: PubMed   Mentions:    Fields:    
    92. Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. Cancer Genomics Proteomics. 2021 May-Jun; 18(3):317-324. Suenaga M, Zhang WU, Mashima T, Schirripa M, Cao S, Okazaki S, Berger MD, Miyamoto Y, Barzi A, Yamaguchi T, Lenz HJ. PMID: 33893084; PMCID: PMC8126324.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    93. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. Eur J Cancer. 2021 06; 150:133-142. Arai H, Millstein J, Loupakis F, Stintzing S, Wang J, Battaglin F, Kawanishi N, Jayachandran P, Soni S, Zhang W, Mumenthaler SM, Cremolini C, Heinemann V, Falcone A, Lenz HJ. PMID: 33901792.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    94. Clocking cancer: the circadian clock as a target in cancer therapy. Oncogene. 2021 05; 40(18):3187-3200. Battaglin F, Chan P, Pan Y, Soni S, Qu M, Spiller ER, Castanon S, Roussos Torres ET, Mumenthaler SM, Kay SA, Lenz HJ. PMID: 33846572; PMCID: PMC8549632.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    95. The Emergence of Baricitinib: A Story of Tortoises Versus Hares. Clin Infect Dis. 2021 04 08; 72(7):1251-1252. Lenz HJ, Richardson P, Stebbing J. PMID: 32901809; PMCID: PMC7499511.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    96. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy. Ann Oncol. 2021 07; 32(7):906-916. Wang JY, Xiu J, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Oberley M, Spetzler D, Shen L, Korn WM, Lenz HJ. PMID: 33798656.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    97. RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Mol Cancer Ther. 2021 06; 20(6):1153-1160. Arai H, Cao S, Battaglin F, Wang J, Kawanishi N, Tokunaga R, Loupakis F, Stintzing S, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. PMID: 33785650.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    98. The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clin Cancer Res. 2021 06 01; 27(11):3234-3242. Arai H, Elliott A, Xiu J, Wang J, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Marshall JL, Lockhart AC, Stafford P, Zhang J, Moretto R, Cremolini C, Korn WM, Lenz HJ. PMID: 33766816.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    99. Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. Sci Rep. 2021 03 11; 11(1):5639. Elliott A, Saul M, Zeng J, Marshall JL, Kim ES, Nagasaka M, Lenz HJ, Schwartzberg L, Spetzler D, Abraham J, Xiu J, Stafford P, Michael Korn W. PMID: 33707526; PMCID: PMC7952699.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    100. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist. 2021 07; 26(7):610-618. Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, Bekaii-Saab T. PMID: 33604969; PMCID: PMC8265366.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    101. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clin Cancer Res. 2021 05 15; 27(10):2723-2733. Wick A, Bähr O, Schuler M, Rohrberg K, Chawla SP, Janku F, Schiff D, Heinemann V, Narita Y, Lenz HJ, Ikeda M, Ando Y, Wick W, Steinbach JP, Burger MC, Wenger K, Lassen U, Sankhala KK, Roggia C, Genvresse I, Munhoz C, Rentzsch C, Reschke S, Langer S, Wagner M, Kaulfuss S, Cai C, Lagkadinou E, Jeffers M, Peña C, Tabatabai G. PMID: 33622704.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    102. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1. Autophagy. 2021 Jan; 17(1):1-382. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, Adamopoulos IE, Adeli K, Adolph TE, Adornetto A, Aflaki E, Agam G, Agarwal A, Aggarwal BB, Agnello M, Agostinis P, Agrewala JN, Agrotis A, Aguilar PV, Ahmad ST, Ahmed ZM, Ahumada-Castro U, Aits S, Aizawa S, Akkoc Y, Akoumianaki T, Akpinar HA, Al-Abd AM, Al-Akra L, Al-Gharaibeh A, Alaoui-Jamali MA, Alberti S, Alcocer-Gómez E, Alessandri C, Ali M, Alim Al-Bari MA, Aliwaini S, Alizadeh J, Almacellas E, Almasan A, Alonso A, Alonso GD, Altan-Bonnet N, Altieri DC, Álvarez ÉMC, Alves S, Alves da Costa C, Alzaharna MM, Amadio M, Amantini C, Amaral C, Ambrosio S, Amer AO, Ammanathan V, An Z, Andersen SU, Andrabi SA, Andrade-Silva M, Andres AM, Angelini S, Ann D, Anozie UC, Ansari MY, Antas P, Antebi A, Antón Z, Anwar T, Apetoh L, Apostolova N, Araki T, Araki Y, Arasaki K, Araújo WL, Araya J, Arden C, Arévalo MA, Arguelles S, Arias E, Arikkath J, Arimoto H, Ariosa AR, Armstrong-James D, Arnauné-Pelloquin L, Aroca A, Arroyo DS, Arsov I, Artero R, Asaro DML, Aschner M, Ashrafizadeh M, Ashur-Fabian O, Atanasov AG, Au AK, Auberger P, Auner HW, Aurelian L, Autelli R, Avagliano L, Ávalos Y, Aveic S, Aveleira CA, Avin-Wittenberg T, Aydin Y, Ayton S, Ayyadevara S, Azzopardi M, Baba M, Backer JM, Backues SK, Bae DH, Bae ON, Bae SH, Baehrecke EH, Baek A, Baek SH, Baek SH, Bagetta G, Bagniewska-Zadworna A, Bai H, Bai J, Bai X, Bai Y, Bairagi N, Baksi S, Balbi T, Baldari CT, Balduini W, Ballabio A, Ballester M, Balazadeh S, Balzan R, Bandopadhyay R, Banerjee S, Banerjee S, Bánréti Á, Bao Y, Baptista MS, Baracca A, Barbati C, Bargiela A, Barilà D, Barlow PG, Barmada SJ, Barreiro E, Barreto GE, Bartek J, Bartel B, Bartolome A, Barve GR, Basagoudanavar SH, Bassham DC, Bast RC, Basu A, Batoko H, Batten I, Baulieu EE, Baumgarner BL, Bayry J, Beale R, Beau I, Beaumatin F, Bechara LRG, Beck GR, Beers MF, Begun J, Behrends C, Behrens GMN, Bei R, Bejarano E, Bel S, Behl C, Belaid A, Belgareh-Touzé N, Bellarosa C, Belleudi F, Belló Pérez M, Bello-Morales R, Beltran JSO, Beltran S, Benbrook DM, Bendorius M, Benitez BA, Benito-Cuesta I, Bensalem J, Berchtold MW, Berezowska S, Bergamaschi D, Bergami M, Bergmann A, Berliocchi L, Berlioz-Torrent C, Bernard A, Berthoux L, Besirli CG, Besteiro S, Betin VM, Beyaert R, Bezbradica JS, Bhaskar K, Bhatia-Kissova I, Bhattacharya R, Bhattacharya S, Bhattacharyya S, Bhuiyan MS, Bhutia SK, Bi L, Bi X, Biden TJ, Bijian K, Billes VA, Binart N, Bincoletto C, Birgisdottir AB, Bjorkoy G, Blanco G, Blas-Garcia A, Blasiak J, Blomgran R, Blomgren K, Blum JS, Boada-Romero E, Boban M, Boesze-Battaglia K, Boeuf P, Boland B, Bomont P, Bonaldo P, Bonam SR, Bonfili L, Bonifacino JS, Boone BA, Bootman MD, Bordi M, Borner C, Bornhauser BC, Borthakur G, Bosch J, Bose S, Botana LM, Botas J, Boulanger CM, Boulton ME, Bourdenx M, Bourgeois B, Bourke NM, Bousquet G, Boya P, Bozhkov PV, Bozi LHM, Bozkurt TO, Brackney DE, Brandts CH, Braun RJ, Braus GH, Bravo-Sagua R, Bravo-San Pedro JM, Brest P, Bringer MA, Briones-Herrera A, Broaddus VC, Brodersen P, Brodsky JL, Brody SL, Bronson PG, Bronstein JM, Brown CN, Brown RE, Brum PC, Brumell JH, Brunetti-Pierri N, Bruno D, Bryson-Richardson RJ, Bucci C, Buchrieser C, Bueno M, Buitrago-Molina LE, Buraschi S, Buch S, Buchan JR, Buckingham EM, Budak H, Budini M, Bultynck G, Burada F, Burgoyne JR, Burón MI, Bustos V, Büttner S, Butturini E, Byrd A, Cabas I, Cabrera-Benitez S, Cadwell K, Cai J, Cai L, Cai Q, Cairó M, Calbet JA, Caldwell GA, Caldwell KA, Call JA, Calvani R, Calvo AC, Calvo-Rubio Barrera M, Camara NO, Camonis JH, Camougrand N, Campanella M, Campbell EM, Campbell-Valois FX, Campello S, Campesi I, Campos JC, Camuzard O, Cancino J, Candido de Almeida D, Canesi L, Caniggia I, et al. PMID: 33634751; PMCID: PMC7996087.
      View in: PubMed   Mentions: 870     Fields:    Translation:HumansAnimalsCells
    103. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics J. 2021 06; 21(3):285-295. Suenaga M, Schirripa M, Cao S, Zhang W, Cremolini C, Lonardi S, Okazaki S, Berger MD, Miyamoto Y, Soni S, Barzi A, Yamaguchi T, Loupakis F, Falcone A, Lenz HJ. PMID: 33542444.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    104. A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemother Pharmacol. 2021 04; 87(4):525-532. Thomas JS, El-Khoueiry AB, Maurer BJ, Groshen S, Pinski JK, Cobos E, Gandara DR, Lenz HJ, Kang MH, Reynolds CP, Newman EM. PMID: 33423090; PMCID: PMC8058950.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    105. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Invest New Drugs. 2021 06; 39(3):812-820. Quinn DI, Tsao-Wei DD, Twardowski P, Aparicio AM, Frankel P, Chatta G, Wright JJ, Groshen SG, Khoo S, Lenz HJ, Lara PN, Gandara DR, Newman E. PMID: 33409898.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    106. Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. Pharmacogenet Genomics. 2021 01; 31(1):10-16. Suenaga M, Cao S, Zhang W, Matsusaka S, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Barzi A, Yamamoto N, Yamaguchi T, Lenz HJ. PMID: 32732498; PMCID: PMC7655616.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    107. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2021 02 01; 39(4):285-294. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. PMID: 33356422; PMCID: PMC8462593.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCTClinical Trials
    108. Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. Oncologist. 2021 02; 26(2):e261-e269. Sobrero A, Lenz HJ, Eng C, Scheithauer W, Middleton G, Chen W, Esser R, Nippgen J, Burris H. PMID: 33191588; PMCID: PMC7873334.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    109. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clin Cancer Res. 2021 02 15; 27(4):1174-1183. Abraham JP, Magee D, Cremolini C, Antoniotti C, Halbert DD, Xiu J, Stafford P, Berry DA, Oberley MJ, Shields AF, Marshall JL, Salem ME, Falcone A, Grothey A, Hall MJ, Venook AP, Lenz HJ, Helmstetter A, Korn WM, Spetzler DB. PMID: 33293373.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    110. Human-specific polymorphic pseudogenization of SIGLEC12 protects against advanced cancer progression. FASEB Bioadv. 2021 Feb; 3(2):69-82. Siddiqui SS, Vaill M, Do R, Khan N, Verhagen AL, Zhang W, Lenz HJ, Johnson-Pais TL, Leach RJ, Fraser G, Wang C, Feng GS, Varki N, Varki A. PMID: 33615152; PMCID: PMC7876704.
      View in: PubMed   Mentions: 10  
    111. All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. JCO Oncol Pract. 2020 12; 16(12):793-798. Innocenti F, Mills SC, Sanoff H, Ciccolini J, Lenz HJ, Milano G. PMID: 33197222; PMCID: PMC8462561.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    112. The structure-function relationship of oncogenic LMTK3. Sci Adv. 2020 11; 6(46). Ditsiou A, Cilibrasi C, Simigdala N, Papakyriakou A, Milton-Harris L, Vella V, Nettleship JE, Lo JH, Soni S, Smbatyan G, Ntavelou P, Gagliano T, Iachini MC, Khurshid S, Simon T, Zhou L, Hassell-Hart S, Carter P, Pearl LH, Owen RL, Owens RJ, Roe SM, Chayen NE, Lenz HJ, Spencer J, Prodromou C, Klinakis A, Stebbing J, Giamas G. PMID: 33188023; PMCID: PMC7673765.
      View in: PubMed   Mentions: 13     Fields:    
    113. Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. J Immunother Cancer. 2020 11; 8(2). Arai H, Xiao Y, Loupakis F, Kawanishi N, Wang J, Battaglin F, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Falcone A, Millstein J, Lenz HJ. PMID: 33172883; PMCID: PMC7656952.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    114. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open. 2020 11; 5(6):e000942. Seeber A, Zimmer K, Kocher F, Puccini A, Xiu J, Nabhan C, Elliott A, Goldberg RM, Grothey A, Shields AF, Battaglin F, El-Deiry WS, Philip PA, Marshall JL, Hall M, Korn WM, Lenz HJ, Wolf D, Feistritzer C, Spizzo G. PMID: 33229504; PMCID: PMC7684832.
      View in: PubMed   Mentions: 17  Translation:Humans
    115. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncol. 2020 Nov 01; 6(11):1713-1721. Mackintosh C, Yuan C, Ou FS, Zhang S, Niedzwiecki D, Chang IW, O'Neil BH, Mullen BC, Lenz HJ, Blanke CD, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg RM, O'Reilly EM, Meyerhardt JA, Ng K. PMID: 32940631; PMCID: PMC7499248.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    116. The impact of ARID1A mutation on molecular characteristics in colorectal cancer. Eur J Cancer. 2020 11; 140:119-129. Tokunaga R, Xiu J, Goldberg RM, Philip PA, Seeber A, Battaglin F, Arai H, Lo JH, Naseem M, Puccini A, Berger MD, Soni S, Zhang W, Chen S, Hwang JJ, Shields AF, Marshall JL, Baba H, Korn WM, Lenz HJ. PMID: 33080474; PMCID: PMC8009046.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    117. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers (Basel). 2020 Oct 13; 12(10). Volz NB, Hanna DL, Stintzing S, Zhang W, Yang D, Cao S, Ning Y, Matsusaka S, Sunakawa Y, Berger MD, Cremolini C, Loupakis F, Falcone A, Lenz HJ. PMID: 33065994; PMCID: PMC7601940.
      View in: PubMed   Mentions: 1  
    118. Molecular Characterization of Appendiceal Goblet Cell Carcinoid. Mol Cancer Ther. 2020 12; 19(12):2634-2640. Arai H, Baca Y, Battaglin F, Kawanishi N, Wang J, Soni S, Zhang W, Millstein J, Johnston C, Goldberg RM, Philip PA, Seeber A, Xiu J, Hwang JJ, Shields AF, Marshall JL, Korn WM, Lenz HJ. PMID: 33037134; PMCID: PMC8011958.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    119. Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. JAMA Netw Open. 2020 10 01; 3(10):e2023500. Van Blarigan EL, Zhang S, Ou FS, Venlo A, Ng K, Atreya C, Van Loon K, Niedzwiecki D, Giovannucci E, Wolfe EG, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. PMID: 33125497; PMCID: PMC7599454.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    120. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS One. 2020; 15(9):e0239439. Miyamoto Y, Schirripa M, Suenaga M, Cao S, Zhang W, Okazaki S, Berger MD, Matsusaka S, Yang D, Ning Y, Baba H, Loupakis F, Lonardi S, Pietrantonio F, Borelli B, Cremolini C, Yamaguchi T, Lenz HJ. PMID: 32970737; PMCID: PMC7514061.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    121. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2021 01 01; 27(1):267-275. Innocenti F, Sibley AB, Patil SA, Etheridge AS, Jiang C, Ou FS, Howell SD, Plummer SJ, Casey G, Bertagnolli MM, McLeod HL, Auman JT, Blanke CD, Furukawa Y, Venook AP, Kubo M, Lenz HJ, Parker JS, Ratain MJ, Owzar K. PMID: 32958699; PMCID: PMC7785628.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    122. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. Clin Colorectal Cancer. 2021 03; 20(1):84-95.e8. Lenz HJ, Argiles G, Yoshino T, Tejpar S, Ciardiello F, Braunger J, Salnikov AV, Gabrielyan O, Schmid R, Höfler J, Kitzing T, Van Cutsem E. PMID: 33041226.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    123. Novel Genomic Differences in Cell-Free Circulating DNA Profiles of Young- Versus Older-Onset Colorectal Cancer. J Adolesc Young Adult Oncol. 2021 06; 10(3):336-341. Barzi A, Weipert CM, Espenschied CR, Lenz HJ. PMID: 32915106.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    124. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Clin Cancer Res. 2020 11 15; 26(22):5943-5951. Puccini A, Poorman K, Salem ME, Soldato D, Seeber A, Goldberg RM, Shields AF, Xiu J, Battaglin F, Berger MD, Tokunaga R, Naseem M, Barzi A, Iqbal S, Zhang W, Soni S, Hwang JJ, Philip PA, Sciallero S, Korn WM, Marshall JL, Lenz HJ. PMID: 32883742; PMCID: PMC8970533.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    125. Risk of Persistent Opioid Use following Major Surgery in Matched Samples of Patients with and without Cancer. Cancer Epidemiol Biomarkers Prev. 2020 11; 29(11):2126-2133. Falcone M, Luo C, Chen Y, Birtwell D, Cheatle M, Duan R, Gabriel PE, He L, Ko EM, Lenz HJ, Mirkovic N, Mowery DL, Ochroch EA, Paulson EC, Schriver E, Schnoll RA, Bekelman JE, Lerman C. PMID: 32859580; PMCID: PMC8074574.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    126. Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer. Oncologist. 2020 12; 25(12):e1879-e1885. Barzi A, Choi A, Tsao-Wei D, Iqbal S, El-Khoueiry A, Agafitei DR, Cologne KG, Lenz HJ. PMID: 32649004; PMCID: PMC8186403.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    127. IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectr. 2021 02; 5(1). Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Pollak MN, Nixon AB, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Benson AB, Atkins JN, Goldberg RM, Brown JC, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA. PMID: 33426464; PMCID: PMC7785047.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    128. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clin Cancer Res. 2020 10 15; 26(20):5348-5357. Dotan E, Cardin DB, Lenz HJ, Messersmith W, O'Neil B, Cohen SJ, Denlinger CS, Shahda S, Astsaturov I, Kapoun AM, Brachmann RK, Uttamsingh S, Stagg RJ, Weekes C. PMID: 32694153; PMCID: PMC7572624.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    129. Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. Clin Cancer Res. 2020 09 15; 26(18):4756-4766. Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PA, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ, Zhang C, Kaur N, Elmonshed D, Galletti G, Sarkar S, Bhinder B, Pittman ME, Plotnikova OM, Kotlov N, Frenkel F, Bagaev A, Elemento O, Betel D, Giannakakou P, Lenz HJ. PMID: 32641434; PMCID: PMC8209413.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    130. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. J Patient Rep Outcomes. 2020 Jul 08; 4(1):54. Wong SF, Unger JM, Wade JL, Wagner LI, Lacouture ME, Humphries KC, Moseley A, Arnold K, Velasco MR, Floyd JD, Esparaz BT, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Hershman DL, Moinpour CM. PMID: 32642992; PMCID: PMC7343679.
      View in: PubMed   Mentions: 1  
    131. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 12; 17(12):757-770. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. PMID: 32632268; PMCID: PMC7790747.
      View in: PubMed   Mentions: 129     Fields:    Translation:Humans
    132. Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers (Basel). 2020 Jun 30; 12(7). Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Murgioni S, Lonardi S, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Barzi A, Loupakis F, Falcone A, Lenz HJ. PMID: 32629861; PMCID: PMC7408001.
      View in: PubMed   Mentions: 3  
    133. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int J Cancer. 2020 11 15; 147(10):2948-2956. Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF, Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. PMID: 32449172; PMCID: PMC7530095.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    134. Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Sci Rep. 2020 06 17; 10(1):9778. Barat A, Smeets D, Moran B, Zhang W, Cao S, Das S, Klinger R, Betge J, Murphy V, Bacon O, Kay EW, Van Grieken NCT, Verheul HMW, Gaiser T, Schulte N, Ebert MP, Fender B, Hennessy BT, McNamara DA, O'Connor D, Gallagher WM, Cremolini C, Loupakis F, Parikh A, Mancao C, Ylstra B, Lambrechts D, Lenz HJ, Byrne AT, Prehn JHM. PMID: 32555399; PMCID: PMC7299973.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    135. Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases. Sci Adv. 2020 06; 6(23):eaba6752. Dai Z, Zhang XN, Nasertorabi F, Cheng Q, Li J, Katz BB, Smbatyan G, Pei H, Louie SG, Lenz HJ, Stevens RC, Zhang Y. PMID: 32537509; PMCID: PMC7269645.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    136. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open. 2020 06; 5(3):e000682. Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz HJ, Seeber A. PMID: 32576609; PMCID: PMC7312328.
      View in: PubMed   Mentions: 42  Translation:HumansCells
    137. Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance. Cancers (Basel). 2020 May 28; 12(6). Garvey CM, Lau R, Sanchez A, Sun RX, Fong EJ, Doche ME, Chen O, Jusuf A, Lenz HJ, Larson B, Mumenthaler SM. PMID: 32481658; PMCID: PMC7352975.
      View in: PubMed   Mentions: 20  
    138. WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. Cancers (Basel). 2020 May 22; 12(5). Zimmer K, Puccini A, Xiu J, Baca Y, Spizzo G, Lenz HJ, Battaglin F, Goldberg RM, Grothey A, Shields AF, Salem ME, Marshall JL, Korn WM, Wolf D, Kocher F, Seeber A. PMID: 32455893; PMCID: PMC7281075.
      View in: PubMed   Mentions: 9  
    139. Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. J Immunother Cancer. 2020 05; 8(1). Puccini A, Battaglin F, Iaia ML, Lenz HJ, Salem ME. PMID: 32393474; PMCID: PMC7223273.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    140. How we treat left-sided vs right-sided colon cancer. Clin Adv Hematol Oncol. 2020 May; 18(5):253-257. Hanna DL, Lenz HJ. PMID: 32628652.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    141. Reply to the letter to the editor 'Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil' by Colloca et al. Ann Oncol. 2020 08; 31(8):1085-1087. Yoshino T, Lenz HJ. PMID: 32360742.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    142. 12-Chemokine signature, a predictor of tumor recurrence in colorectal cancer. Int J Cancer. 2020 07 15; 147(2):532-541. Tokunaga R, Nakagawa S, Sakamoto Y, Nakamura K, Naseem M, Izumi D, Kosumi K, Taki K, Higashi T, Miyata T, Miyamoto Y, Yoshida N, Baba H, Lenz HJ. PMID: 32191346; PMCID: PMC9371443.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    143. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. Eur J Cancer. 2020 05; 131:89-97. Berger MD, Ning Y, Stintzing S, Heinemann V, Cao S, Zhang W, Yang D, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Tokunaga R, Naseem M, Battaglin F, Cremolini C, Falcone A, Loupakis F, Lenz HJ. PMID: 32305727; PMCID: PMC7513926.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    144. Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectr. 2020 Jun; 4(3):pkaa024. Guercio BJ, Zhang S, Venook AP, Ou FS, Niedzwiecki D, Lenz HJ, Innocenti F, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Brown JC, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA. PMID: 33134818; PMCID: PMC7590517.
      View in: PubMed   Mentions: 5     Fields:    
    145. Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. Br J Cancer. 2020 05; 122(10):1518-1524. Stremitzer S, Vermeulen P, Graver S, Kockx M, Dirix L, Yang D, Zhang W, Stift J, Wrba F, Gruenberger T, Lenz HJ, Scherer SJ. PMID: 32205863; PMCID: PMC7217855.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    146. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. J Surg Oncol. 2020 Jun; 121(8):1320-1328. Stein MK, Williard FW, Xiu J, Tsao MW, Martin MG, Deschner BW, Dickson PV, Glazer ES, Yakoub D, Shibata D, Grothey AF, Philip PA, Hwang JJ, Shields AF, Marshall JL, Korn WM, Lenz HJ, Deneve JL. PMID: 32166754; PMCID: PMC7505122.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    147. Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). Eur J Surg Oncol. 2020 06; 46(6):955-966. Ren L, Zhu D, Benson AB, Nordlinger B, Koehne CH, Delaney CP, Kerr D, Lenz HJ, Fan J, Wang J, Gu J, Li J, Shen L, Tsarkov P, Tejpar S, Zheng S, Zhang S, Gruenberger T, Qin X, Wang X, Zhang Z, Poston GJ, Xu J, SINCE (Shanghai International Consensus Expert Group on Colorectal Liver Metastases) Group. PMID: 32147426.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    148. Partition: a surjective mapping approach for dimensionality reduction. Bioinformatics. 2020 02 01; 36(3):676-681. Millstein J, Battaglin F, Barrett M, Cao S, Zhang W, Stintzing S, Heinemann V, Lenz HJ. PMID: 31504178; PMCID: PMC8215926.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    149. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Cancer Sci. 2020 Feb; 111(2):441-450. Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz HJ. PMID: 31821662; PMCID: PMC7004533.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    150. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol. 2020 01; 31(1):88-95. Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, Falcone A, Yamazaki K, Nishina T, Garcia-Carbonero R, Komatsu Y, Baba H, Argilés G, Tsuji A, Sobrero A, Yamaguchi K, Peeters M, Muro K, Zaniboni A, Sugimoto N, Shimada Y, Tsuji Y, Hochster HS, Moriwaki T, Tran B, Esaki T, Hamada C, Tanase T, Benedetti F, Makris L, Yamashita F, Lenz HJ. PMID: 31912801; PMCID: PMC7491979.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    151. Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology. 2020 04; 158(5):1274-1286.e12. Archambault AN, Su YR, Jeon J, Thomas M, Lin Y, Conti DV, Win AK, Sakoda LC, Lansdorp-Vogelaar I, Peterse EFP, Zauber AG, Duggan D, Holowatyj AN, Huyghe JR, Brenner H, Cotterchio M, Bézieau S, Schmit SL, Edlund CK, Southey MC, MacInnis RJ, Campbell PT, Chang-Claude J, Slattery ML, Chan AT, Joshi AD, Song M, Cao Y, Woods MO, White E, Weinstein SJ, Ulrich CM, Hoffmeister M, Bien SA, Harrison TA, Hampe J, Li CI, Schafmayer C, Offit K, Pharoah PD, Moreno V, Lindblom A, Wolk A, Wu AH, Li L, Gunter MJ, Gsur A, Keku TO, Pearlman R, Bishop DT, Castellví-Bel S, Moreira L, Vodicka P, Kampman E, Giles GG, Albanes D, Baron JA, Berndt SI, Brezina S, Buch S, Buchanan DD, Trichopoulou A, Severi G, Chirlaque MD, Sánchez MJ, Palli D, Kühn T, Murphy N, Cross AJ, Burnett-Hartman AN, Chanock SJ, de la Chapelle A, Easton DF, Elliott F, English DR, Feskens EJM, FitzGerald LM, Goodman PJ, Hopper JL, Hudson TJ, Hunter DJ, Jacobs EJ, Joshu CE, Küry S, Markowitz SD, Milne RL, Platz EA, Rennert G, Rennert HS, Schumacher FR, Sandler RS, Seminara D, Tangen CM, Thibodeau SN, Toland AE, van Duijnhoven FJB, Visvanathan K, Vodickova L, Potter JD, Männistö S, Weigl K, Figueiredo J, Martín V, Larsson SC, Parfrey PS, Huang WY, Lenz HJ, Castelao JE, Gago-Dominguez M, Muñoz-Garzón V, Mancao C, Haiman CA, Wilkens LR, Siegel E, Barry E, Younghusband B, Van Guelpen B, Harlid S, Zeleniuch-Jacquotte A, Liang PS, Du M, Casey G, Lindor NM, Le Marchand L, Gallinger SJ, Jenkins MA, Newcomb PA, Gruber SB, Schoen RE, Hampel H, Corley DA, Hsu L, Peters U, Hayes RB. PMID: 31866242; PMCID: PMC7103489.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    152. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. Oncologist. 2020 05; 25(5):404-413. Salem ME, Battaglin F, Goldberg RM, Puccini A, Shields AF, Arguello D, Korn WM, Marshall JL, Grothey A, Lenz HJ. PMID: 31848314; PMCID: PMC7216442.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    153. Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer. Oncotarget. 2019 Dec 17; 10(66):7016-7030. Gerdtsson AS, Thiele JA, Shishido SN, Zheng S, Schaffer R, Bethel K, Curley S, Lenz HJ, Hanna DL, Nieva J, Kolatkar A, Ruiz C, Rodriguez-Lee M, Oakley Iii GJ, Lee JSH, Hicks J, Kuhn P. PMID: 31903162; PMCID: PMC6925029.
      View in: PubMed   Mentions: 8     Fields:    
    154. Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. J Clin Oncol. 2020 02 10; 38(5):472-479. Iqbal S, McDonough S, Lenz HJ, Ilson D, Burtness B, Nangia CS, Barzi A, Schneider CJ, Liu JJ, Dotan E, Guthrie KA, Hochster HS. PMID: 31815582; PMCID: PMC7007287.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    155. Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. Mol Ther. 2020 02 05; 28(2):536-547. Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang JE, Epstein AL, Lenz HJ, Zhang Y. PMID: 31843452; PMCID: PMC7001084.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansAnimalsCells
    156. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann Oncol. 2019 11 01; 30(11):1796-1803. Stintzing S, Wirapati P, Lenz HJ, Neureiter D, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Al-Batran S, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Modest DP, Jung A, Kirchner T, Aderka D, Tejpar S, Heinemann V. PMID: 31868905; PMCID: PMC6927316.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCTClinical Trials
    157. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2020 02 15; 26(4):846-854. Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn PZ, He P, McDevitt J, Sheth S, Englert JM, Ku GY. PMID: 31676670; PMCID: PMC7748730.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCellsCTClinical Trials
    158. Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev. 2019 Dec; 81:101912. Arai H, Battaglin F, Wang J, Lo JH, Soni S, Zhang W, Lenz HJ. PMID: 31715423; PMCID: PMC7491975.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    159. Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectr. 2020 Feb; 4(1):pkz078. Brown JC, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Denlinger CS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. PMID: 32259016; PMCID: PMC7043296.
      View in: PubMed   Mentions: 14     Fields:    
    160. Novel Circulating Tumor Cell Assay for Detection of Colorectal Adenomas and Cancer. Clin Transl Gastroenterol. 2019 10; 10(10):e00088. Tsai WS, You JF, Hung HY, Hsieh PS, Hsieh B, Lenz HJ, Idos G, Friedland S, Yi-Jiun Pan J, Shao HJ, Wu JC, Lai JM, Chang SE, Mei R, Watson D, Javey M, Nimgaonkar A. PMID: 31663904; PMCID: PMC6884354.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    161. Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2019 12 15; 25(24):7497-7505. Yuan C, Sato K, Hollis BW, Zhang S, Niedzwiecki D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K. PMID: 31548349; PMCID: PMC6911644.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    162. Publisher Correction: Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 Sep 23; 10(1):4386. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubinski J, Maehle L, Maier C, Mannermaa A, Marchand LL, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AAA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjørge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, Aguado-Barrera ME, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Wolk A, Woll P, Woods M, et al. PMID: 31548585; PMCID: PMC6757065.
      View in: PubMed   Mentions: 1     Fields:    
    163. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. Cancer Chemother Pharmacol. 2019 12; 84(6):1201-1208. Luu T, Frankel P, Beumer JH, Lim D, Cristea M, Appleman LJ, Lenz HJ, Gandara DR, Kiesel BF, Piekarz RL, Newman EM. PMID: 31522242; PMCID: PMC6821594.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    164. Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. Clin Colorectal Cancer. 2019 12; 18(4):269-279.e5. Lenz HJ, Argiles G, Yoshino T, Lonardi S, Falcone A, Limón ML, Sobrero A, Hastedt C, Peil B, Voss F, Griebsch I, Van Cutsem E. PMID: 31628043; PMCID: PMC7505163.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    165. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br J Clin Pharmacol. 2019 11; 85(11):2499-2511. Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP. PMID: 31271459; PMCID: PMC6848909.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    166. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Clin Oncol. 2019 10 10; 37(29):2620-2631. Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. PMID: 31408415; PMCID: PMC6900834.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    167. What Should We Do Better? Lessons from Negative Results of a Biomarker Validation Study. J Natl Cancer Inst. 2019 08 01; 111(8):754-756. Battaglin F, Lenz HJ. PMID: 30649462; PMCID: PMC6695307.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    168. Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims. Arch Osteoporos. 2019 07 28; 14(1):83. Barzi A, Hershman DL, Till C, Barlow WE, Ramsey S, Lenz HJ, Hochster HS, Unger JM. PMID: 31352608; PMCID: PMC6852789.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    169. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 06; 38(3):821-830. Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, Kapoun AM, Stagg RJ, Berlin J, Messersmith WA, Cohen SJ. PMID: 31338636; PMCID: PMC7211194.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCellsCTClinical Trials
    170. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. PLoS One. 2019; 14(7):e0219469. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS. PMID: 31291332; PMCID: PMC6620013.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    171. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine. 2019 Jul; 45:139-154. Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, Betge J, Härtel N, Kather JN, Weis CA, Gaiser T, Marx A, Weiss C, Hofheinz R, Miller IS, Loupakis F, Lenz HJ, Byrne AT, Ebert MP. PMID: 31300350; PMCID: PMC6642438.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    172. Reply to S. Sorscher. J Clin Oncol. 2019 09 01; 37(25):2291-2293. Innocenti F, Ou FS, Qu X, Zemla T, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O. PMID: 31268798.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    173. The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer. Cancer Manag Res. 2019; 11:5911-5924. Battaglin F, Puccini A, Ahcene Djaballah S, Lenz HJ. PMID: 31388315; PMCID: PMC6607986.
      View in: PubMed   Mentions: 12  
    174. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019 08; 20(8):1070-1082. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. PMID: 31262657; PMCID: PMC9187307.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    175. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 2019 07; 51(7):1113-1122. Hu Z, Ding J, Ma Z, Sun R, Seoane JA, Scott Shaffer J, Suarez CJ, Berghoff AS, Cremolini C, Falcone A, Loupakis F, Birner P, Preusser M, Lenz HJ, Curtis C. PMID: 31209394; PMCID: PMC6982526.
      View in: PubMed   Mentions: 176     Fields:    Translation:Humans
    176. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. Int J Cancer. 2019 11 01; 145(9):2450-2458. Weekes C, Lockhart AC, Lee JJ, Sturm I, Cleton A, Huang F, Lenz HJ. PMID: 30958892; PMCID: PMC6771657.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    177. Conversations About Financial Issues in Routine Oncology Practices: A Multicenter Study. J Oncol Pract. 2019 08; 15(8):e690-e703. Warsame R, Kennedy CC, Kumbamu A, Branda M, Fernandez C, Kimball B, Leppin AL, O'Byrne T, Jatoi A, Lenz HJ, Tilburt JC. PMID: 31162996; PMCID: PMC6804867.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    178. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist. 2019 11; 24(11):1453-1461. Morse MA, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, Atasoy A, Shangguan T, Zhao H, El-Rayes B. PMID: 31147488; PMCID: PMC6853093.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCellsCTClinical Trials
    179. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019 07; 69(4):305-343. El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL. PMID: 31116423; PMCID: PMC6767457.
      View in: PubMed   Mentions: 108     Fields:    Translation:Humans
    180. A Multicenter Comparison of Complementary and Alternative Medicine (CAM) Discussions in Oncology Care: The Role of Time, Patient-Centeredness, and Practice Context. Oncologist. 2019 11; 24(11):e1180-e1189. Tilburt J, Yost KJ, Lenz HJ, Zúñiga ML, O'Byrne T, Branda ME, Leppin AL, Kimball B, Fernandez C, Jatoi A, Barwise A, Kumbamu A, Montori V, Koenig BA, Geller G, Larson S, Roter DL. PMID: 31101701; PMCID: PMC6853106.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    181. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2019 08 01; 37(22):1876-1885. Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O. PMID: 31042420; PMCID: PMC6675593.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCTClinical Trials
    182. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. Int J Cancer. 2019 10 15; 145(8):2082-2090. Tokunaga R, Cao S, Naseem M, Battaglin F, Lo JH, Arai H, Loupakis F, Stintzing S, Puccini A, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. PMID: 30856283; PMCID: PMC7491977.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    183. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. J Clin Oncol. 2019 05 10; 37(14):1217-1227. Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O. PMID: 30865548; PMCID: PMC6506418.
      View in: PubMed   Mentions: 140     Fields:    Translation:Humans
    184. Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. Eur J Cancer. 2019 04; 111:138-147. Puccini A, Loupakis F, Stintzing S, Cao S, Battaglin F, Togunaka R, Naseem M, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. PMID: 30852420; PMCID: PMC6436973.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    185. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective. Am J Health Syst Pharm. 2019 Feb 21; 76(6):339-348. Chan BM, Hochster HS, Lenz HJ. PMID: 31361848.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    186. Safety and Tolerability of c-MET Inhibitors in Cancer. Drug Saf. 2019 02; 42(2):211-233. Puccini A, Marín-Ramos NI, Bergamo F, Schirripa M, Lonardi S, Lenz HJ, Loupakis F, Battaglin F. PMID: 30649748; PMCID: PMC7491978.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimals
    187. Novel Common Genetic Susceptibility Loci for Colorectal Cancer. J Natl Cancer Inst. 2019 02 01; 111(2):146-157. Schmit SL, Edlund CK, Schumacher FR, Gong J, Harrison TA, Huyghe JR, Qu C, Melas M, Van Den Berg DJ, Wang H, Tring S, Plummer SJ, Albanes D, Alonso MH, Amos CI, Anton K, Aragaki AK, Arndt V, Barry EL, Berndt SI, Bezieau S, Bien S, Bloomer A, Boehm J, Boutron-Ruault MC, Brenner H, Brezina S, Buchanan DD, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Castelao JE, Chan AT, Chang-Claude J, Chanock SJ, Cheng I, Cheng YW, Chin LS, Church JM, Church T, Coetzee GA, Cotterchio M, Cruz Correa M, Curtis KR, Duggan D, Easton DF, English D, Feskens EJM, Fischer R, FitzGerald LM, Fortini BK, Fritsche LG, Fuchs CS, Gago-Dominguez M, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Giovannucci EL, Gogarten SM, Gonzalez-Villalpando C, Gonzalez-Villalpando EM, Grady WM, Greenson JK, Gsur A, Gunter M, Haiman CA, Hampe J, Harlid S, Harju JF, Hayes RB, Hofer P, Hoffmeister M, Hopper JL, Huang SC, Huerta JM, Hudson TJ, Hunter DJ, Idos GE, Iwasaki M, Jackson RD, Jacobs EJ, Jee SH, Jenkins MA, Jia WH, Jiao S, Joshi AD, Kolonel LN, Kono S, Kooperberg C, Krogh V, Kuehn T, Küry S, LaCroix A, Laurie CA, Lejbkowicz F, Lemire M, Lenz HJ, Levine D, Li CI, Li L, Lieb W, Lin Y, Lindor NM, Liu YR, Loupakis F, Lu Y, Luh F, Ma J, Mancao C, Manion FJ, Markowitz SD, Martin V, Matsuda K, Matsuo K, McDonnell KJ, McNeil CE, Milne R, Molina AJ, Mukherjee B, Murphy N, Newcomb PA, Offit K, Omichessan H, Palli D, Cotoré JPP, Pérez-Mayoral J, Pharoah PD, Potter JD, Qu C, Raskin L, Rennert G, Rennert HS, Riggs BM, Schafmayer C, Schoen RE, Sellers TA, Seminara D, Severi G, Shi W, Shibata D, Shu XO, Siegel EM, Slattery ML, Southey M, Stadler ZK, Stern MC, Stintzing S, Taverna D, Thibodeau SN, Thomas DC, Trichopoulou A, Tsugane S, Ulrich CM, van Duijnhoven FJB, van Guelpan B, Vijai J, Virtamo J, Weinstein SJ, White E, Win AK, Wolk A, Woods M, Wu AH, Wu K, Xiang YB, Yen Y, Zanke BW, Zeng YX, Zhang B, Zubair N, Kweon SS, Figueiredo JC, Zheng W, Marchand LL, Lindblom A, Moreno V, Peters U, Casey G, Hsu L, Conti DV, Gruber SB. PMID: 29917119; PMCID: PMC6555904.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    188. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. Clin Cancer Res. 2019 05 15; 25(10):3096-3103. Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Naseem M, Lo JH, Arai H, Battaglin F, Puccini A, Berger MD, Soni S, Zhang W, Hwang JJ, Shields AF, Marshall JL, Baba H, Korn WM, Lenz HJ. PMID: 30692096; PMCID: PMC6886223.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    189. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubinski J, Maehle L, Maier C, Mannermaa A, Marchand LL, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AAA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjørge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, Aguado-Barrera ME, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, et al. PMID: 30683880; PMCID: PMC6347624.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    190. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Oncologist. 2019 07; 24(7):921-932. Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, Hochster HS, Scappaticci F, Palma JF, Price R, Lee JJ, Nicholas A, Sommer N, Bendell J. PMID: 30552157; PMCID: PMC6656450.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    191. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. Eur J Cancer. 2019 01; 107:100-114. Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ. PMID: 30554073; PMCID: PMC6367121.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    192. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. Int J Cancer. 2019 05 15; 144(10):2567-2577. Suenaga M, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Yamaguchi T, Lenz HJ. PMID: 30411783; PMCID: PMC7497849.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    193. B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev. 2019 Feb; 73:10-19. Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, Berger MD, Zhang W, Baba H, Lenz HJ. PMID: 30551036; PMCID: PMC7505165.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansAnimalsCells
    194. A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol. 2018 12; 41(12):1193-1198. Chen EY, Blanke CD, Haller DG, Benson AB, Dragovich T, Lenz HJ, Robles C, Li H, Mori M, Mattek N, Sanborn RE, Lopez CD. PMID: 29782360; PMCID: PMC6240505.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    195. Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. Br J Cancer. 2018 12; 119(12):1451-1455. Loupakis F, Hurwitz HI, Saltz L, Arnold D, Grothey A, Nguyen QL, Osborne S, Talbot J, Srock S, Lenz HJ. PMID: 30487637; PMCID: PMC6288128.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    196. Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity. J Am Chem Soc. 2018 12 05; 140(48):16413-16417. Cheng Q, Shi X, Han M, Smbatyan G, Lenz HJ, Zhang Y. PMID: 30452238; PMCID: PMC6469991.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansAnimalsCells
    197. Management of Advanced Small Bowel Cancer. Curr Treat Options Oncol. 2018 11 05; 19(12):69. Puccini A, Battaglin F, Lenz HJ. PMID: 30397729; PMCID: PMC7489287.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    198. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol. 2018 Nov; 16(11):735-745. Battaglin F, Naseem M, Lenz HJ, Salem ME. PMID: 30543589; PMCID: PMC7493692.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    199. Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer. Mol Cancer Ther. 2018 12; 17(12):2788-2795. Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y, Moran M, Astrow SH, Hsiang J, Stephens C, Fujii M, Ichikawa W. PMID: 30275242; PMCID: PMC7497846.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    200. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest. 2018 11 01; 128(11):4912-4923. Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon M, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Läubli H. PMID: 30130255; PMCID: PMC6205408.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCells
    201. MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. Clin Cancer Res. 2019 05 15; 25(10):2988-2995. Parikh AR, Lee FC, Yau L, Koh H, Knost J, Mitchell EP, Bosanac I, Choong N, Scappaticci F, Mancao C, Lenz HJ. PMID: 30224341; PMCID: PMC9022943.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    202. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. Clin Colorectal Cancer. 2019 03; 18(1):e8-e19. Tokunaga R, Cao S, Naseem M, Lo JH, Battaglin F, Puccini A, Berger MD, Soni S, Millstein J, Zhang W, Stintzing S, Loupakis F, Cremolini C, Heinemann V, Falcone A, Lenz HJ. PMID: 30293873; PMCID: PMC6416082.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    203. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Ann Oncol. 2018 09 01; 29(9):1955-1963. Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limón ML, Saunders M, Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F, Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G. PMID: 30010751; PMCID: PMC6158765.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    204. Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018 12; 17(4):e741-e749. Sunakawa Y, Yang D, Cao S, Zhang W, Moran M, Astrow SH, Hsiang J, Stephens C, Tsuji A, Takahashi T, Tanioka H, Negoro Y, Takagane A, Tani S, Yamaguchi T, Eto T, Fujii M, Ichikawa W, Lenz HJ. PMID: 30219280; PMCID: PMC6249067.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    205. Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist. 2019 03; 24(3):319-326. Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA, Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME. PMID: 30018131; PMCID: PMC6519749.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    206. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell Int. 2018; 18:99. Battaglin F, Naseem M, Puccini A, Lenz HJ. PMID: 30008616; PMCID: PMC6042434.
      View in: PubMed   Mentions: 28  
    207. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics J. 2018 09; 18(5):623-632. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Lonardi S, Bergamo F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ. PMID: 29925895; PMCID: PMC6151284.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    208. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 10 01; 24(19):4734-4744. Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL. PMID: 29871907; PMCID: PMC6168379.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    209. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. Oncologist. 2018 11; 23(11):1319-1327. Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA, Marshall JL, Goldberg RM. PMID: 29866946; PMCID: PMC6291329.
      View in: PubMed   Mentions: 84     Fields:    Translation:Humans
    210. Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. Clin Colorectal Cancer. 2018 09; 17(3):215-222.e3. McSkane M, Stintzing S, Heinemann V, Puccini A, Naseem M, Cao S, Lenz HJ, Jelas I. PMID: 29880436; PMCID: PMC7496217.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    211. Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochem Biophys Res Commun. 2018 06 07; 500(3):621-625. Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi R, Gonzales R, Grino M, Pinski JK, Barzi A, Raez LE, Eberhardt WE, Theegarten D, Lenz HJ, Uetake H, Danenberg PV, Danenberg K. PMID: 29679564; PMCID: PMC9165692.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    212. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies. Oncol Res Treat. 2018; 41(5):313-315. Moehler M, Göpfert K, Lenz HJ. PMID: 29705792; PMCID: PMC7493693.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    213. Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. Clin Cancer Res. 2018 08 15; 24(16):3829-3837. Shah MA, Starodub A, Sharma S, Berlin J, Patel M, Wainberg ZA, Chaves J, Gordon M, Windsor K, Brachmann CB, Huang X, Vosganian G, Maltzman JD, Smith V, Silverman JA, Lenz HJ, Bendell JC. PMID: 29691300; PMCID: PMC7496223.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    214. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev. 2018 May; 66:15-22. Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, Battaglin F, Soni S, McSkane M, Zhang W, Lenz HJ. PMID: 29631196; PMCID: PMC5964025.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCells
    215. Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer. Cancers (Basel). 2018 Mar 29; 10(4). Manegold P, Lai KKY, Wu Y, Teo JL, Lenz HJ, Genyk YS, Pandol SJ, Wu K, Lin DP, Chen Y, Nguyen C, Zhao Y, Kahn M. PMID: 29596326; PMCID: PMC5923350.
      View in: PubMed   Mentions: 27  
    216. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clin Colorectal Cancer. 2018 09; 17(3):e471-e488. Hanna DL, Loupakis F, Yang D, Cremolini C, Schirripa M, Li M, Matsusaka S, Berger MD, Miyamoto Y, Zhang W, Ning Y, Antoniotti C, Salvatore L, Moran M, Zeger G, Astrow SH, Falcone A, Lenz HJ. PMID: 29636300; PMCID: PMC6110978.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    217. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. Br J Cancer. 2018 04; 118(7):938-946. Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK, Hetman R, Dudley MW, Zeng J, Nickner C, Xiong H, Komarnitsky P, Shepherd SP, Hurwitz H, Lenz HJ. PMID: 29527010; PMCID: PMC5933261.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    218. NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One. 2018; 13(3):e0193640. Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ. PMID: 29522543; PMCID: PMC5844536.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    219. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Mol Cancer Res. 2018 05; 16(5):805-812. Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ. PMID: 29523759; PMCID: PMC6833953.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    220. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018 05; 81(5):957-963. El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR. PMID: 29520435; PMCID: PMC6330274.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    221. Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. J Cancer Metastasis Treat. 2018; 4(3). Battaglin F, Puccini A, Naseem M, Schirripa M, Berger MD, Tokunaga R, McSkane M, Khoukaz T, Soni S, Zhang W, Lenz HJ. PMID: 34532592; PMCID: PMC8442855.
      View in: PubMed   Mentions: 2  
    222. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clin Colorectal Cancer. 2018 06; 17(2):e395-e414. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz HJ. PMID: 29606345; PMCID: PMC7493703.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    223. First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors. Invest New Drugs. 2018 10; 36(5):860-868. Keedy VL, Lenz HJ, Saltz L, Whisenant JG, Berlin JD, Camacho LH. PMID: 29376210; PMCID: PMC7507839.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    224. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 03 10; 36(8):773-779. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T. PMID: 29355075.
      View in: PubMed   Mentions: 906     Fields:    Translation:HumansCells
    225. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev Anticancer Ther. 2018 03; 18(3):251-266. Battaglin F, Puccini A, Intini R, Schirripa M, Ferro A, Bergamo F, Lonardi S, Zagonel V, Lenz HJ, Loupakis F. PMID: 29338550; PMCID: PMC7493706.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    226. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018 02; 90:63-72. Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M, Longo-Munoz F, Portales F, Ciardiello F, Siena S, Yamaguchi K, Muro K, Denda T, Tsuji Y, Makris L, Loehrer P, Lenz HJ, Ohtsu A, RECOURSE Study Group. PMID: 29274618; PMCID: PMC7493695.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    227. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clin Cancer Res. 2018 02 15; 24(4):784-793. Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ. PMID: 29208668; PMCID: PMC7505162.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    228. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018 Feb; 63:48-60. Ferris RL, Lenz HJ, Trotta AM, García-Foncillas J, Schulten J, Audhuy F, Merlano M, Milano G. PMID: 29223828; PMCID: PMC7505164.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    229. Colorectal cancer in 2017: Practice-changing updates in the adjuvant and metastatic setting. Nat Rev Clin Oncol. 2018 02; 15(2):77-78. Puccini A, Lenz HJ. PMID: 29182161; PMCID: PMC7491976.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    230. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2018 Feb; 63:40-47. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ. PMID: 29207310; PMCID: PMC5801162.
      View in: PubMed   Mentions: 546     Fields:    Translation:HumansAnimals
    231. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. Br J Cancer. 2018 01; 118(2):181-188. Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz HJ, Raoul JL, Meropol NJ, Lombard-Bohas C, Posey J, Faivre S, Raymond E, Valle JW. PMID: 29161241; PMCID: PMC5785750.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    232. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Ann Oncol. 2017 Nov 01; 28(11):2780-2785. Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S, Zhang W, Falcone A, Loupakis F, Lenz HJ. PMID: 29045529; PMCID: PMC5834083.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    233. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. Clin Colorectal Cancer. 2018 03; 17(1):e121-e125. Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. PMID: 29233486; PMCID: PMC6598683.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    234. Trends in colorectal cancer mortality in hispanics: a SEER analysis. Oncotarget. 2017 Dec 12; 8(65):108771-108777. Barzi A, Yang D, Mostofizadeh S, Lenz HJ. PMID: 29312566; PMCID: PMC5752479.
      View in: PubMed   Mentions: 9     Fields:    
    235. Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. Cancer Chemother Pharmacol. 2017 Dec; 80(6):1161-1169. Lenz HJ, Philip P, Saunders M, Kolevska T, Mukherjee K, Samuel L, Bondarde S, Dobbs T, Tagliaferri M, Hoch U, Hannah AL, Berkowitz M. PMID: 29043412; PMCID: PMC6863159.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    236. DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies. Oncogene. 2018 02 01; 37(5):566-577. Weisenberger DJ, Liang G, Lenz HJ. PMID: 28991233; PMCID: PMC7491233.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    237. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer. 2017 11; 86:197-206. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, Salvatore L, Borelli B, Pietrantonio F, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ. PMID: 28992563; PMCID: PMC7497848.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    238. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017 Oct 17; 8(49):86356-86368. Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL. PMID: 29156800; PMCID: PMC5689690.
      View in: PubMed   Mentions: 89     Fields:    
    239. Colorectal cancer: epigenetic alterations and their clinical implications. Biochim Biophys Acta Rev Cancer. 2017 Dec; 1868(2):439-448. Puccini A, Berger MD, Naseem M, Tokunaga R, Battaglin F, Cao S, Hanna DL, McSkane M, Soni S, Zhang W, Lenz HJ. PMID: 28939182; PMCID: PMC5757873.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    240. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017 10; 84:69-80. Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. PMID: 28787661; PMCID: PMC7505124.
      View in: PubMed   Mentions: 133     Fields:    Translation:Humans
    241. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017 Aug 01; 28(8):1713-1729. Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F. PMID: 28407110; PMCID: PMC6246616.
      View in: PubMed   Mentions: 345     Fields:    Translation:Humans
    242. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 09; 18(9):1182-1191. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T. PMID: 28734759; PMCID: PMC6207072.
      View in: PubMed   Mentions: 1164     Fields:    Translation:HumansCellsCTClinical Trials
    243. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer. 2017 Nov 15; 123(22):4506-4514. Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD, Miyamoto Y, Suenaga M, Iqubal S, Barzi A, Cremolini C, Falcone A, Battaglin F, Salvatore L, Borelli B, Helentjaris TG, Lenz HJ. PMID: 28708932; PMCID: PMC5673544.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    244. Biomarker-driven and molecular targeted therapies for colorectal cancers. Semin Oncol. 2018 06; 45(3):124-132. Schirripa M, Cohen SA, Battaglin F, Lenz HJ. PMID: 30262397; PMCID: PMC7496213.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    245. New perspectives for colorectal cancer. Oncotarget. 2017 Jun 27; 8(26):41782-41783. Puccini A, Lenz HJ. PMID: 28620138; PMCID: PMC5522023.
      View in: PubMed   Mentions:    Fields:    
    246. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. Cancer. 2017 Oct 01; 123(19):3732-3743. Ricker CN, Hanna DL, Peng C, Nguyen NT, Stern MC, Schmit SL, Idos GE, Patel R, Tsai S, Ramirez V, Lin S, Shamasunadara V, Barzi A, Lenz HJ, Figueiredo JC. PMID: 28640387; PMCID: PMC5610604.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    247. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer. 2017 09 15; 141(6):1222-1230. Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ. PMID: 28569041; PMCID: PMC5528002.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    248. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C. PMID: 28632865; PMCID: PMC5545896.
      View in: PubMed   Mentions: 382     Fields:    Translation:Humans
    249. What We Know About Stage II and III Colon Cancer: It's Still Not Enough. Target Oncol. 2017 06; 12(3):265-275. Puccini A, Berger MD, Zhang W, Lenz HJ. PMID: 28504299; PMCID: PMC7489295.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    250. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. Int J Cancer. 2017 07 15; 141(2):383-392. Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ. PMID: 28369940; PMCID: PMC5510747.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    251. Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Ann Oncol. 2017 05 01; 28(5):1015-1022. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ. PMID: 28453695; PMCID: PMC5834058.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    252. Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. Pharmacogenomics J. 2018 04; 18(2):262-269. Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A, Miyamoto Y, Mizunuma N, Lenz HJ. PMID: 28398355; PMCID: PMC7505125.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    253. Mindfulness practice reduces cortisol blunting during chemotherapy: A randomized controlled study of colorectal cancer patients. Cancer. 2017 Aug 15; 123(16):3088-3096. Black DS, Peng C, Sleight AG, Nguyen N, Lenz HJ, Figueiredo JC. PMID: 28387949; PMCID: PMC5544546.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    254. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov. 2017 06; 7(6):610-619. van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM. PMID: 28363909; PMCID: PMC5546207.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCTClinical Trials
    255. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. Eur J Cancer. 2017 05; 77:13-20. Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ. PMID: 28347919; PMCID: PMC7497847.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    256. What roles do colon stem cells and gap junctions play in the left and right location of origin of colorectal cancers? J Cell Commun Signal. 2017 Mar; 11(1):79-87. Trosko JE, Lenz HJ. PMID: 28220297; PMCID: PMC5362582.
      View in: PubMed   Mentions: 5  
    257. Five-year mortality in patients treated for severe community-acquired pneumonia - a retrospective study. Acta Anaesthesiol Scand. 2017 Apr; 61(4):418-426. Lenz H, Norby GO, Dahl V, Ranheim TE, Haagensen RE. PMID: 28164259.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    258. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2017 Feb 01; 3(2):194-201. Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V. PMID: 27722750; PMCID: PMC7505121.
      View in: PubMed   Mentions: 306     Fields:    
    259. Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 05 01; 123(9):1516-1527. Barzi A, Lenz HJ, Quinn DI, Sadeghi S. PMID: 28117881; PMCID: PMC6879196.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    260. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017 Jul 15; 23(14):3657-3666. Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. PMID: 28096270; PMCID: PMC5511562.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    261. Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis. Pharmacogenomics J. 2017 12; 17(6):535-542. Morgen EK, Lenz HJ, Jonker DJ, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis CS, Dobrovic A, O'Callaghan CJ, Liu G. PMID: 27897268; PMCID: PMC9536193.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    262. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. Oncologist. 2017 01; 22(1):107-114. Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM. PMID: 27821793; PMCID: PMC5313270.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    263. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res. 2016 Nov 01; 22(21):5204-5210. Khalil DN, Postow MA, Ibrahim N, Ludwig DL, Cosaert J, Kambhampati SR, Tang S, Grebennik D, Kauh JS, Lenz HJ, Flaherty KT, Hodi FS, Lawrence DP, Wolchok JD. PMID: 27797971; PMCID: PMC5117650.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    264. A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J. 2018 01; 18(1):43-48. Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ. PMID: 27698403; PMCID: PMC5378677.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    265. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016; 1(5):e000097. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. PMID: 27843641; PMCID: PMC5070299.
      View in: PubMed   Mentions: 48  
    266. Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. Mol Cancer Ther. 2016 11; 15(11):2814-2821. Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift J, Wrba F, Gruenberger T, Lenz HJ. PMID: 27535973; PMCID: PMC8547597.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    267. Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget. 2016 Aug 16; 7(33):53668-53678. Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ. PMID: 27449091; PMCID: PMC5288213.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    268. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. Pharmacogenomics J. 2018 01; 18(1):29-34. Ning Y, Zhang W, Hanna DL, Yang D, Okazaki S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, El-Khoueiry A, Lenz HJ. PMID: 27503579; PMCID: PMC7505126.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    269. CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics J. 2017 12; 17(6):543-550. Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ. PMID: 27503580; PMCID: PMC7496215.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    270. Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. Indian J Surg Oncol. 2017 Dec; 8(4):580-590. Miyamoto Y, Zhang W, Lenz HJ. PMID: 29203992; PMCID: PMC5705494.
      View in: PubMed   Mentions: 2  
    271. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment. Clin Cancer Res. 2016 Aug 15; 22(16):3999-4004. Miyamoto Y, Hanna DL, Zhang W, Baba H, Lenz HJ. PMID: 27340276; PMCID: PMC4987228.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    272. A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. Mol Cancer Ther. 2016 09; 15(9):2251-8. LaBonte MJ, Yang D, Zhang W, Wilson PM, Nagarwala YM, Koch KM, Briner C, Kaneko T, Rha SY, Gladkov O, Urba SG, Sakaeva D, Pishvaian MJ, Hsieh RK, Lee WP, Lenz HJ. PMID: 27325685; PMCID: PMC7496218.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    273. CDX2 as a Prognostic Biomarker in Colon Cancer. N Engl J Med. 2016 06 02; 374(22):2183. Schirripa M, Loupakis F, Lenz HJ. PMID: 27248629; PMCID: PMC7521111.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    274. Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. Pharmacogenomics J. 2017 12; 17(6):528-534. Sunakawa Y, Cao S, Volz NB, Berger MD, Yang D, Parekh A, Zhang W, Matsusaka S, Ning Y, Stremitzer S, Stintzing S, Sebio A, Okazaki S, Wakatsuki T, Azuma M, Watanabe M, Koizumi W, Wu AH, Lenz HJ. PMID: 27241062; PMCID: PMC7507965.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    275. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. Mol Cancer Ther. 2016 07; 15(7):1740-5. Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ. PMID: 27196764; PMCID: PMC4936942.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    276. Biomarker in Colorectal Cancer. Cancer J. 2016 May-Jun; 22(3):156-64. Schirripa M, Lenz HJ. PMID: 27341592; PMCID: PMC4955946.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    277. Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer. Cancer Biol Ther. 2016 07 02; 17(7):751-9. Sunakawa Y, Yang D, Moran M, Astrow SH, Tsuji A, Stephens C, Zhang W, Cao S, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Masuishi T, Takeuchi M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ. PMID: 27104867; PMCID: PMC4970538.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    278. Genome-wide association study of colorectal cancer in Hispanics. Carcinogenesis. 2016 06; 37(6):547-556. Schmit SL, Schumacher FR, Edlund CK, Conti DV, Ihenacho U, Wan P, Van Den Berg D, Casey G, Fortini BK, Lenz HJ, Tusié-Luna T, Aguilar-Salinas CA, Moreno-Macías H, Huerta-Chagoya A, Ordóñez-Sánchez ML, Rodríguez-Guillén R, Cruz-Bautista I, Rodríguez-Torres M, Muñóz-Hernández LL, Arellano-Campos O, Gómez D, Alvirde U, González-Villalpando C, González-Villalpando ME, Le Marchand L, Haiman CA, Figueiredo JC. PMID: 27207650; PMCID: PMC4876992.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    279. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Rev Clin Pharmacol. 2016 Aug; 9(8):1091-108. Hanna DL, Lenz HJ. PMID: 27031164; PMCID: PMC7493705.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    280. The safety of monoclonal antibodies for treatment of colorectal cancer. Expert Opin Drug Saf. 2016 Jun; 15(6):799-808. Berger MD, Lenz HJ. PMID: 26982510.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    281. Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. Clin Colorectal Cancer. 2016 12; 15(4):e221-e227. Shabihkhani M, Yu SS, Yang D, Lin S, Hamilton AS, Lenz HJ, Barzi A. PMID: 27553907; PMCID: PMC9159474.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    282. Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand? Nat Rev Gastroenterol Hepatol. 2016 05; 13(5):258-9. Schirripa M, Lenz HJ. PMID: 27006256; PMCID: PMC7493690.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    283. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Mol Cancer Ther. 2016 06; 15(6):1405-11. Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W, Mizunuma N, Lenz HJ. PMID: 26983880; PMCID: PMC4893985.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    284. Gradual withdrawal of remifentanil infusion may prevent opioid-induced hyperalgesia. Br J Anaesth. 2016 Apr; 116(4):524-30. Comelon M, Raeder J, Stubhaug A, Nielsen CS, Draegni T, Lenz H. PMID: 26934941.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    285. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clin Cancer Res. 2016 07 01; 22(13):3218-26. Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ. PMID: 26839145; PMCID: PMC4930688.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    286. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Crit Rev Oncol Hematol. 2016 Apr; 100:117-26. Sunakawa Y, Schirripa M, Lenz HJ. PMID: 26850575; PMCID: PMC4799732.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    287. A novel antimetabolite: TAS-102 for metastatic colorectal cancer. Expert Rev Clin Pharmacol. 2016; 9(3):355-65. Miyamoto Y, Lenz HJ, Baba H. PMID: 26677869; PMCID: PMC7485169.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    288. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist. 2016 Feb; 21(2):172-7. Leichman L, Groshen S, O'Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, Hamilton SR, Hochster HS. PMID: 26786262; PMCID: PMC4746089.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCellsCTClinical Trials
    289. Genetic variants associated with colorectal brain metastases susceptibility and survival. Pharmacogenomics J. 2017 01; 17(1):29-35. Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A, Mendez A, Berger MD, El-Khoueiry R, Birner P, Preusser M, Lenz HJ. PMID: 26689941; PMCID: PMC7493704.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    290. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23. Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE. PMID: 26598548; PMCID: PMC4722891.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    291. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92. Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. PMID: 26527777; PMCID: PMC4678179.
      View in: PubMed   Mentions: 245     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    292. Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer. Pharmacogenomics J. 2017 01; 17(1):36-41. Sunakawa Y, Cao S, Berger MD, Matsusaka S, Yang D, Zhang W, Ning Y, Parekh A, Stremitzer S, Mendez A, Okazaki S, Wakatsuki T, Azuma M, Shimada K, Watanabe M, Koizumi W, Wu AH, Lenz HJ. PMID: 26503819; PMCID: PMC7496219.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    293. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J Clin Oncol. 2016 Jan 10; 34(2):144-50. Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ. PMID: 26503203; PMCID: PMC5070548.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    294. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. Ann Oncol. 2015 Dec; 26(12):2450-6. Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ. PMID: 26416897; PMCID: PMC4658546.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsCTClinical Trials
    295. Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. Clin Cancer Res. 2015 Nov 15; 21(22):5002-7. Sebio A, Lenz HJ. PMID: 26384319; PMCID: PMC4644679.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    296. Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. Pharmacogenomics J. 2016 08; 16(4):312-9. Sebio A, Matsusaka S, Zhang W, Yang D, Ning Y, Stremitzer S, Stintzing S, Sunakawa Y, Yamauchi S, Fujimoto Y, Ueno M, Lenz HJ. PMID: 26370619; PMCID: PMC4792794.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    297. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol. 2015 Nov; 76(5):897-907. Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM. PMID: 26362045; PMCID: PMC4694049.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    298. Response. J Natl Cancer Inst. 2015 Sep; 107(9). Cremolini C, Loupakis F, Lenz HJ. PMID: 26389154; PMCID: PMC4836811.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    299. Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. Thromb Res. 2015 Nov; 136(5):865-9. Bianconi D, Schuler A, Pausz C, Geroldinger A, Kaider A, Lenz HJ, Kornek G, Scheithauer W, Zielinski CC, Pabinger I, Ay C, Prager GW. PMID: 26440977; PMCID: PMC7496222.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    300. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther. 2015 Oct; 14(10):2401-8. Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ. PMID: 26227487; PMCID: PMC4596790.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    301. Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Mol Cancer Ther. 2015 Oct; 14(10):2374-81. Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, Loupakis F, Cremolini C, Falcone A, Lenz HJ. PMID: 26206335; PMCID: PMC4596768.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    302. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015 Aug; 16(8):937-48. Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. PMID: 26184520; PMCID: PMC7513622.
      View in: PubMed   Mentions: 146     Fields:    Translation:Humans
    303. Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasiveness. Sci Rep. 2015 Jun 08; 5:11207. Lee NS, Evgrafov OV, Souaiaia T, Bonyad A, Herstein J, Lee JY, Kim J, Ning Y, Sixto M, Weitz AC, Lenz HJ, Wang K, Knowles JA, Press MF, Salvaterra PM, Shung KK, Chow RH. PMID: 26053433; PMCID: PMC4459148.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    304. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev. 2015 Nov; 41(9):777-83. Lenz HJ, Stintzing S, Loupakis F. PMID: 26428513; PMCID: PMC4624296.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansAnimals
    305. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14; 372(20):1909-19. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A, RECOURSE Study Group. PMID: 25970050.
      View in: PubMed   Mentions: 493     Fields:    Translation:HumansCTClinical Trials
    306. Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. Ann Oncol. 2015 Aug; 26(8):1728-33. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Sebio A, Yamauchi S, Matsusaka S, Parekh A, Barzi A, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ. PMID: 25957329; PMCID: PMC4511220.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    307. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer. 2015 Jul; 51(10):1243-52. Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S. PMID: 25937522; PMCID: PMC7508202.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCTClinical Trials
    308. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci U S A. 2015 May 12; 112(19):E2487-96. Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP, Lanza DG, Berger NA, Markowitz SD, Lenz HJ, Nadeau JH, Pizarro TT, Heaney JD. PMID: 25918379; PMCID: PMC4434739.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansAnimalsCells
    309. Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. Curr Treat Options Oncol. 2015 Apr; 16(4):17. Sunakawa Y, Lenz HJ. PMID: 25813036.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    310. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. Br J Cancer. 2015 Mar 31; 112(7):1199-205. Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV. PMID: 25756398; PMCID: PMC4385961.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    311. Pharmacogenomics of fluorouracil -based chemotherapy toxicity. Expert Opin Drug Metab Toxicol. 2015 May; 11(5):811-21. Matsusaka S, Lenz HJ. PMID: 25800061.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    312. Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. Pharmacogenomics J. 2015 Dec; 15(6):521-9. Stremitzer S, Sunakawa Y, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Yamauchi S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ. PMID: 25752522; PMCID: PMC7505123.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    313. Cost-effectiveness of genomic testing for colorectal cancer: are we there yet? Oncology (Williston Park). 2015 Mar; 29(3):183-4; 186. Barzi A, Lenz HJ. PMID: 25783978.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    314. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015 Mar; 107(3). Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ. PMID: 25713148; PMCID: PMC4565528.
      View in: PubMed   Mentions: 217     Fields:    Translation:Humans
    315. Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. Cancer. 2015 Jun 01; 121(11):1898-905. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ. PMID: 25690670; PMCID: PMC4441595.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    316. LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy. Pharmacogenomics J. 2015 Oct; 15(5):391-6. Szkandera J, Herzog S, Pichler M, Stiegelbauer V, Stotz M, Schaberl-Moser R, Samonigg H, Asslaber M, Lax S, Leitner G, Renner W, Lenz HJ, Berghold A, Gerger A. PMID: 25665511; PMCID: PMC4762902.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    317. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. Hematol Oncol Clin North Am. 2015 Feb; 29(1):43-60. Stintzing S, Stremitzer S, Sebio A, Lenz HJ. PMID: 25475572.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    318. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015 Mar 01; 33(7):692-700. Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F. PMID: 25605843.
      View in: PubMed   Mentions: 361     Fields:    Translation:HumansCTClinical Trials
    319. Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clin Cancer Res. 2015 Apr 01; 21(7):1583-90. Bohanes P, Rankin CJ, Blanke CD, Winder T, Ulrich CM, Smalley SR, Rich TA, Martensen JA, Benson AB, Mayer RJ, Cripps CM, Danenberg K, Makar KW, Zhang W, Benedetti JK, Lenz HJ. PMID: 25589620; PMCID: PMC4566931.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    320. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015 Mar; 75(3):537-46. Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH. PMID: 25567350; PMCID: PMC4344391.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    321. Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer. Pharmacogenet Genomics. 2015 Jan; 25(1):30-7. Sebio A, Gerger A, Matsusaka S, Yang D, Zhang W, Stremitzer S, Stintzing S, Sunakawa Y, Yamauchi S, Ning Y, Fujimoto Y, Ueno M, Lenz HJ. PMID: 25379721; PMCID: PMC4260998.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    322. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J. 2015 Aug; 15(4):354-62. Maus MK, Hanna DL, Stephens CL, Astrow SH, Yang D, Grimminger PP, Loupakis F, Hsiang JH, Zeger G, Wakatsuki T, Barzi A, Lenz HJ. PMID: 25532759; PMCID: PMC4478287.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    323. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. Pharmacogenomics J. 2015 Jun; 15(3):226-34. Bohanes P, Yang D, Loupakis F, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F, Wakatsuki T, Zhang W, Benhaim L, El-Khoueiry A, El-Khoueiry R, Lenz HJ. PMID: 25487679.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    324. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2015 May 10; 33(14):1551-6. Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C. PMID: 25488966; PMCID: PMC4417726.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    325. Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics. 2014 Dec; 24(12):588-96. Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M, Watanabe M, Koizumi W, Lenz HJ. PMID: 25203738; PMCID: PMC4218879.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    326. Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. Ann Oncol. 2015 Feb; 26(2):332-9. Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, Ning Y, Yamauchi S, Stintzing S, Sebio A, El-Khoueiry R, Matsusaka S, Parekh A, Barzi A, Azuma M, Watanabe M, Koizumi W, Lenz HJ. PMID: 25411415; PMCID: PMC4304380.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    327. Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. Pharmacogenet Genomics. 2014 Nov; 24(11):539-47. Wakatsuki T, Stintzing S, Zhang W, Yang D, Azuma M, Ning Y, Yamauchi S, Matsusaka S, Volz NB, Sunakawa Y, Koizumi W, Watanabe M, Barzi A, El Khoueiry AB, Shah MA, Lenz HJ. PMID: 25203737; PMCID: PMC4190127.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    328. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer. 2014 Dec 09; 111(12):2268-74. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. PMID: 25349975; PMCID: PMC4264453.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    329. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan; 75(1):17-23. Hochster HS, Uboha N, Messersmith W, Gold PJ, ONeil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. PMID: 25322874.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    330. Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer. Pharmacogenomics J. 2015 Jun; 15(3):235-40. Benhaim L, Zhang W, Wakatsuki T, Yang D, Gerger A, Bohanes P, Paez D, Loupakis F, LaBonte MJ, Ning Y, El-Khoueiry R, Ladner R, Wilson P, Zhang H, Giamas G, Stebbing J, Lenz HJ. PMID: 25287073.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    331. So much effort, so little progress? J Natl Cancer Inst. 2014 Oct; 106(10). Lenz HJ, Stintzing S. PMID: 25246612.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    332. Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci. 2014 Sep; 105(9):1087-92. Lenz HJ, Kahn M. PMID: 24975284; PMCID: PMC4175086.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansAnimalsCells
    333. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin Cancer Res. 2014 Sep 01; 20(17):4499-4510. Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S. PMID: 25183481; PMCID: PMC4155520.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    334. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol. 2015 Jun; 20(3):518-24. Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN. PMID: 25091263; PMCID: PMC4318776.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    335. Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis. Cancer. 2014 Dec 01; 120(23):3707-16. Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, Lenz HJ, Setiawan VW, El-Khoueiry A. PMID: 25081299; PMCID: PMC9191612.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    336. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics J. 2015 Feb; 15(1):69-76. Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry RE, Li JE, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer SJ, Lenz HJ. PMID: 25069475.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    337. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer. 2014 Oct 01; 120(19):2980-5. Philip PA, Goldman B, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP, Wakatsuki T, Iqbal S, Gaur R, Benedetti JK, Blanke CD. PMID: 25041791; PMCID: PMC4284963.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCellsCTClinical Trials
    338. Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304). Cancer. 2014 Nov 01; 120(21):3329-3337. Ulrich CM, Rankin C, Toriola AT, Makar KW, Altug-Teber Ö, Benedetti JK, Holmes RS, Smalley SR, Blanke CD, Lenz HJ. PMID: 25041994; PMCID: PMC4259283.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    339. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut. 2015 Jun; 64(6):921-8. Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S. PMID: 25011934.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    340. The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁. Sci Signal. 2014 Jun 17; 7(330):ra58. Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, Lombardo Y, Frampton AE, Green AR, Ellis IO, Ali S, Lenz HJ, Thanou M, Stebbing J, Giamas G. PMID: 24939894.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    341. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep. 2014 Jun 26; 7(6):1940-55. Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG. PMID: 24931611.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    342. KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. Oncogene. 2015 Apr 16; 34(16):2103-14. Stebbing J, Zhang H, Xu Y, Lit LC, Green AR, Grothey A, Lombardo Y, Periyasamy M, Blighe K, Zhang W, Shaw JA, Ellis IO, Lenz HJ, Giamas G. PMID: 24909178.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    343. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer. Cancer Med. 2014 Aug; 3(4):988-97. Lin EH, Lenz HJ, Saleh MN, Mackenzie MJ, Knost JA, Pathiraja K, Langdon RB, Yao SL, Lu BD. PMID: 24905030; PMCID: PMC4303167.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    344. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun; 13(6):843-51. Stremitzer S, Sebio A, Stintzing S, Lenz HJ. PMID: 24766434.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    345. Molecular pathways: turning proteasomal protein degradation into a unique treatment approach. Clin Cancer Res. 2014 Jun 15; 20(12):3064-70. Stintzing S, Lenz HJ. PMID: 24756373; PMCID: PMC4703318.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    346. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014 May; 11(5):282-98. Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD. PMID: 24732946.
      View in: PubMed   Mentions: 159     Fields:    Translation:HumansCells
    347. The potential of targeting Wnt/β-catenin in colon cancer. Expert Opin Ther Targets. 2014 Jun; 18(6):611-5. Sebio A, Kahn M, Lenz HJ. PMID: 24702624.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansCells
    348. Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014 Aug; 32(4):682-90. Bendell JC, Lenz HJ, Ryan T, El-Rayes BF, Marshall JL, Modiano MR, Hart LL, Kingsley CD, George TJ, Nakashima D, Berlin JD. PMID: 24691674.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    349. Panitumumab : leading to better overall survival in metastatic colorectal cancer? Expert Opin Biol Ther. 2014 Apr; 14(4):535-48. Sebio A, Stintzing S, Stremitzer S, Zhang W, Lenz HJ. PMID: 24593265.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    350. Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. Pharmacogenomics J. 2014 Aug; 14(4):322-7. Loupakis F, Antoniotti C, Cremolini C, Zhang W, Yang D, Wakatsuki T, Bohanes P, Schirripa M, Salvatore L, Masi G, Ricci V, Graziano F, Ruzzo A, Benhaim L, Marmorino F, Ning Y, El-Khoueiry R, Falcone A, Lenz HJ. PMID: 24513691.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    351. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer. 2014 Feb 18; 110(4):882-7. El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ, Blanke CD. PMID: 24423918; PMCID: PMC3929880.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCellsCTClinical Trials
    352. CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development. Int J Cancer. 2014 Jul 01; 135(1):232-7. Lee YS, Choi D, Kim NY, Yang S, Jung E, Hong M, Yang D, Lenz HJ, Hong YK. PMID: 24338666; PMCID: PMC4166491.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    353. Testing for RAS mutations in patients with metastatic colorectal cancer. Clin Adv Hematol Oncol. 2014 Jan; 12(1):48-9. Lenz HJ. PMID: 25000315.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    354. Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. Yu S, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ, Sadeghi S, Barzi A. PMID: 24188686.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    355. RAS mutations in colorectal cancer. N Engl J Med. 2013 11 28; 369(22):2159. Sunakawa Y, Lenz HJ, Ichikawa W. PMID: 24283233.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    356. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. Lung Cancer. 2014 Feb; 83(2):163-7. Maus MK, Grimminger PP, Mack PC, Astrow SH, Stephens C, Zeger G, Hsiang J, Brabender J, Friedrich M, Alakus H, Hölscher AH, Lara P, Danenberg KD, Lenz HJ, Gandara DR. PMID: 24331409.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    357. A small cog in a big wheel: PIK3CA mutations in colorectal cancer. J Natl Cancer Inst. 2013 Dec 04; 105(23):1775-6. Stintzing S, Lenz HJ. PMID: 24231451.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    358. Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle. Pharmacogenomics. 2013 Nov; 14(14):1671-4. LaBonte MJ, Lenz HJ. PMID: 24192114.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    359. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. Mol Cancer Ther. 2014 Feb; 13(2):528-39. Ning Y, Gerger A, Zhang W, Hanna DL, Yang D, Winder T, Wakatsuki T, Labonte MJ, Stintzing S, Volz N, Sunakawa Y, Stremitzer S, El-Khoueiry R, Lenz HJ. PMID: 24170770; PMCID: PMC3945969.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    360. Listening in on difficult conversations: an observational, multi-center investigation of real-time conversations in medical oncology. BMC Cancer. 2013 Oct 04; 13:455. Kimball BC, James KM, Yost KJ, Fernandez CA, Kumbamu A, Leppin AL, Robinson ME, Geller G, Roter DL, Larson SM, Lenz HJ, Garcia AA, Braddock CH, Jatoi A, de Nuncio ML, Montori VM, Koenig BA, Tilburt JC. PMID: 24093624; PMCID: PMC3850997.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    361. Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). Br J Cancer. 2013 Oct 01; 109(7):1744-9. Louie SG, Ely B, Lenz HJ, Albain KS, Gotay C, Coleman D, Raghavan D, Shields AF, Gold PJ, Blanke CD. PMID: 24022189; PMCID: PMC3790171.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    362. Molecular pathways: Estrogen pathway in colorectal cancer. Clin Cancer Res. 2013 Nov 01; 19(21):5842-8. Barzi A, Lenz AM, Labonte MJ, Lenz HJ. PMID: 23965904; PMCID: PMC3836673.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansAnimalsCells
    363. Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together! Expert Opin Pharmacother. 2013 Nov; 14(16):2203-20. Stintzing S, Lenz HJ. PMID: 23941461.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    364. Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. Mol Cancer Ther. 2013 Oct; 12(10):2261-72. Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ. PMID: 23918832; PMCID: PMC3810398.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    365. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One. 2013; 8(7):e66774. Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ. PMID: 23861747; PMCID: PMC3701556.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    366. Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence. Pharmacogenomics J. 2014 Apr; 14(2):142-50. Páez D, Gerger A, Zhang W, Yang D, Labonte MJ, Benhanim L, Kahn M, Lenz F, Lenz C, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ. PMID: 23817222.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    367. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Cancer. 2013 Aug 15; 119(16):3043-51. Kwak EL, Shapiro GI, Cohen SM, Becerra CR, Lenz HJ, Cheng WF, Su WC, Robohn M, Le Maulf F, Lobmeyer MT, Chand VK, Iafrate AJ. PMID: 23775486.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    368. Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy. Pharmacogenomics J. 2014 Apr; 14(2):135-41. Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte MJ, Ning Y, El-Khoueiry R, Loupakis F, Zhang W, Laurent-Puig P, Lenz HJ. PMID: 23752739.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    369. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jul; 72(1):85-91. Iqbal S, Lenz HJ, Gandara DR, Shibata SI, Groshen S, Synold TW, Newman EM. PMID: 23712328; PMCID: PMC3779138.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    370. MicroRNA-21 in colorectal cancer: "Just another brick in the wall"? J Natl Cancer Inst. 2013 Jun 19; 105(12):840-1. Stintzing S, Lenz HJ. PMID: 23704279.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    371. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2013 Jul 01; 19(13):3631-9. Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM. PMID: 23653147; PMCID: PMC3700623.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    372. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin. J Urol. 2013 Oct; 190(4):1200-4. Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz HJ, Lee CT, Wilson SS, Benson M, Lerner SP, Tangen CM, Thompson IM. PMID: 23597452; PMCID: PMC4113593.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    373. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014 Feb; 32(1):113-22. Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng K. PMID: 23568716; PMCID: PMC3775976.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    374. The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy. Pharmacogenomics J. 2014 Apr; 14(2):130-4. Absenger G, Benhaim L, Szkandera J, Zhang W, Yang D, Labonte MJ, Pichler M, Stotz M, Samonigg H, Renner W, Gerger A, Lenz HJ. PMID: 23567490.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    375. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013 Jul; 24(7):1754-1761. Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ, Press MF. PMID: 23524864; PMCID: PMC3690906.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    376. Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. Pharmacogenomics J. 2014 Feb; 14(1):28-34. Winder T, Giamas G, Wilson PM, Zhang W, Yang D, Bohanes P, Ning Y, Gerger A, Stebbing J, Lenz HJ. PMID: 23459444.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    377. Reply to J. Zhang et al. J Clin Oncol. 2013 Feb 20; 31(6):816-7. Bohanes P, Yang D, Lenz HJ. PMID: 23544202.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    378. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013 Mar 20; 31(9):1219-30. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. PMID: 23401453.
      View in: PubMed   Mentions: 158     Fields:    Translation:Humans
    379. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Invest New Drugs. 2013 Aug; 31(4):845-57. Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD. PMID: 23299388.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    380. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26; 381(9863):303-12. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, CORRECT Study Group. PMID: 23177514.
      View in: PubMed   Mentions: 1137     Fields:    Translation:HumansCTClinical Trials
    381. Assessing the in vivo efficacy of biologic antiangiogenic therapies. Cancer Chemother Pharmacol. 2013 Jan; 71(1):1-12. Wilson PM, LaBonte MJ, Lenz HJ. PMID: 23053262.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    382. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013 Feb; 15(2):106-15. Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. PMID: 23297721; PMCID: PMC3719916.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    383. Interleukin-8 reduces post-surgical lymphedema formation by promoting lymphatic vessel regeneration. Angiogenesis. 2013 Jan; 16(1):29-44. Choi I, Lee YS, Chung HK, Choi D, Ecoiffier T, Lee HN, Kim KE, Lee S, Park EK, Maeng YS, Kim NY, Ladner RD, Petasis NA, Koh CJ, Chen L, Lenz HJ, Hong YK. PMID: 22945845; PMCID: PMC4166493.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    384. Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers? J Hepatobiliary Pancreat Sci. 2012 Sep; 19(5):528-35. Benhaim L, Loupakis F, Labonte MJ, Lenz HJ. PMID: 22735932.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    385. Targeted therapies: Cetuximab dosing by rash--is the scaling of EVEREST meaningful? Nat Rev Clin Oncol. 2012 Oct; 9(10):554-6. Stintzing S, Lenz HJ. PMID: 22889974.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    386. Angiogenesis-related agents in esophageal cancer. Expert Opin Biol Ther. 2012 Oct; 12(10):1335-45. Barzi A, Lenz HJ. PMID: 22860627.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    387. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. Clin Cancer Res. 2012 Oct 01; 18(19):5412-26. Stevenson L, Allen WL, Turkington R, Jithesh PV, Proutski I, Stewart G, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG. PMID: 22859720; PMCID: PMC3463501.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    388. Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). Pharmacogenomics J. 2013 Oct; 13(5):410-6. Wilson PM, Yang D, Azuma M, Shi MM, Danenberg KD, Lebwohl D, Sherrod A, Ladner RD, Zhang W, Danenberg PV, Trarbach T, Folprecht G, Meinhardt G, Lenz HJ. PMID: 22664478.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    389. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer. 2012 May 22; 106(11):1833-41. Lee YS, Choi I, Ning Y, Kim NY, Khatchadourian V, Yang D, Chung HK, Choi D, LaBonte MJ, Ladner RD, Nagulapalli Venkata KC, Rosenberg DO, Petasis NA, Lenz HJ, Hong YK. PMID: 22617157; PMCID: PMC3364111.
      View in: PubMed   Mentions: 154     Fields:    Translation:HumansAnimals
    390. Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol. 2012 Jun 20; 30(18):2265-72. Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, Gerger A, Benhaim L, Paez D, Wakatsuki T, Loupakis F, El-Khoueiry R, Zhang W, Lenz HJ. PMID: 22585694; PMCID: PMC3397720.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    391. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac Oncol. 2012 May; 7(5):906-12. Tomblyn MB, Goldman BH, Thomas CR, Benedetti JK, Lenz HJ, Mehta V, Beeker T, Gold PJ, Abbruzzese JL, Blanke CD, SWOG GI Committee. PMID: 22481235; PMCID: PMC3382003.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    392. Targeting IL-8 in colorectal cancer. Expert Opin Ther Targets. 2012 May; 16(5):491-7. Ning Y, Lenz HJ. PMID: 22494524.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    393. An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence. Pharmacogenomics J. 2013 Aug; 13(4):342-8. Winder T, Wilson PM, Yang D, Zhang W, Ning Y, Power DG, Bohanes P, Gerger A, Tang LH, Shah M, Lenz HJ. PMID: 22491017.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    394. Explaining the unexplainable: EGFR antibodies in colorectal cancer. J Clin Oncol. 2012 May 20; 30(15):1735-7. Grothey A, Lenz HJ. PMID: 22473160.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    395. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther. 2012 Jun; 11(6):1353-64. Ning Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ. PMID: 22391039.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansAnimalsCells
    396. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012 Mar 15; 18(6):1726-34. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. PMID: 22307137; PMCID: PMC3306481.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCTClinical Trials
    397. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am. 2012 Mar; 41(1):189-209. Páez D, Labonte MJ, Lenz HJ. PMID: 22341258.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    398. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J. 2013 Apr; 13(2):173-80. Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ. PMID: 22231565; PMCID: PMC3326190.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    399. "HER majesty's a pretty nice girl but she changes from day to day". J Clin Oncol. 2012 Feb 01; 30(4):465-6; author reply 466-7. Bohanes P, Loupakis F, Labonte MJ, Wakatsuki T, Lenz HJ. PMID: 22203763.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    400. Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives. Scand J Gastroenterol. 2012 Mar; 47(3):325-39. Benhaim L, Labonte MJ, Lenz HJ. PMID: 22182673.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    401. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer. Mol Cancer Ther. 2012 Mar; 11(3):616-28. Wilson PM, LaBonte MJ, Lenz HJ, Mack PC, Ladner RD. PMID: 22172489.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    402. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res. 2012 Feb 01; 18(3):645-53. Páez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ. PMID: 22156560.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCells
    403. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2012 Mar; 69(3):835-43. Chao J, Synold TW, Morgan RJ, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y. PMID: 22105720; PMCID: PMC3288125.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    404. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer. Mol Cancer Ther. 2012 Jan; 11(1):119-31. Allen WL, Stevenson L, Coyle VM, Jithesh PV, Proutski I, Carson G, Gordon MA, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG. PMID: 22027693; PMCID: PMC3272421.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    405. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol. 2011 Dec 01; 29(34):4555-60. Leichman LP, Goldman BH, Bohanes PO, Lenz HJ, Thomas CR, Billingsley KG, Corless CL, Iqbal S, Gold PJ, Benedetti JK, Danenberg KD, Blanke CD. PMID: 22025151; PMCID: PMC3236655.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    406. The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jun; 23(6):1455-64. Labonte MJ, Wilson PM, Yang D, Zhang W, Ladner RD, Ning Y, Gerger A, Bohanes PO, Benhaim L, El-Khoueiry R, El-Khoueiry A, Lenz HJ. PMID: 21989330; PMCID: PMC3360546.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    407. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011 Nov 01; 17(21):6934-43. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ. PMID: 21918173.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    408. Predictive molecular classifiers in colorectal cancer. Semin Oncol. 2011 Aug; 38(4):576-87. Bohanes P, LaBonte MJ, Winder T, Lenz HJ. PMID: 21810517.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    409. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5783-92. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ. PMID: 21791631; PMCID: PMC3174848.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    410. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials. Pharmacogenomics J. 2012 Oct; 12(5):404-11. Grimminger PP, Shi M, Barrett C, Lebwohl D, Danenberg KD, Brabender J, Vigen CL, Danenberg PV, Winder T, Lenz HJ. PMID: 21788964.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    411. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1646-51. El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD. PMID: 21748296; PMCID: PMC3490705.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    412. LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat. 2012 Apr; 132(2):537-44. Stebbing J, Filipovic A, Ellis IO, Green AR, D'Silva TR, Lenz HJ, Coombes RC, Wang T, Lee SC, Giamas G. PMID: 21671015.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    413. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res. 2011 Aug 01; 17(15):5161-9. Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, Grimminger PP, Hölscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K, Machiels JP, Sempoux C, Rödel C, Bracko M, Velenik V, Lenz HJ. PMID: 21673069; PMCID: PMC3149732.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    414. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1597-606. Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. PMID: 21629990.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    415. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011 Jun; 2(2):77-84. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ. PMID: 22811834; PMCID: PMC3397601.
      View in: PubMed   Mentions: 103  
    416. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med. 2011 Jun; 17(6):715-9. Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa BA, Photiou A, Tralau-Stewart C, Castellano L, Green AR, Coombes RC, Ellis IO, Ali S, Lenz HJ, Stebbing J. PMID: 21602804.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimals
    417. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1595-602. Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD. PMID: 21556747; PMCID: PMC3519425.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    418. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res. 2011 May 15; 17(10):3469-77. Grimminger PP, Danenberg P, Dellas K, Arnold D, Rödel C, Machiels JP, Haustermans K, Debucquoy A, Velenik V, Sempoux C, Bracko M, Hölscher AH, Semrau R, Yang D, Danenberg K, Lenz HJ, Vallböhmer D. PMID: 21558395.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    419. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011 May 01; 128(9):2038-49. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, Ladner RD, Lenz HJ. PMID: 20648559; PMCID: PMC3039715.
      View in: PubMed   Mentions: 208     Fields:    Translation:HumansAnimalsCells
    420. A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer. 2011 Sep; 10(3):157-64. Bohanes P, Labonte MJ, Lenz HJ. PMID: 21855036.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    421. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1439-47. Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, Hamilton A, LoRusso PA, Shibata S, Lenz HJ, Mier J, Sarantopoulos J, Mani S, Wright JJ, Ivy SP, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D. PMID: 21479634; PMCID: PMC3481841.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    422. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011 May 15; 71(10):3635-48. LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD. PMID: 21464044; PMCID: PMC3118510.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    423. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs. 2012 Jun; 30(3):1175-83. El-Khoueiry AB, Ramanathan RK, Yang DY, Zhang W, Shibata S, Wright JJ, Gandara D, Lenz HJ. PMID: 21424698; PMCID: PMC3745766.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    424. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol. 2011 Dec; 22(12):2610-2615. Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI, Blanke CD. PMID: 21415234; PMCID: PMC3221514.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCTClinical Trials
    425. GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients. Ann Oncol. 2011 Nov; 22(11):2431-2439. Winder T, Bohanes P, Zhang W, Yang D, Power DG, Ning Y, Gerger A, Wilson PM, Tang LH, Shah M, Lee AS, Lenz HJ. PMID: 21382870; PMCID: PMC3200220.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    426. Molecular predictors of response to antiangiogenesis therapies. Cancer J. 2011 Mar-Apr; 17(2):134-41. Gerger A, LaBonte M, Lenz HJ. PMID: 21427557.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    427. Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. Int J Cancer. 2011 Sep 01; 129(5):1096-104. Winder T, Ning Y, Yang D, Zhang W, Power DG, Bohanes P, Gerger A, Wilson PM, Lurje G, Tang LH, Shah M, Lenz HJ. PMID: 21105049; PMCID: PMC3139396.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    428. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. PMID: 20142723.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    429. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res. 2011 Mar 15; 17(6):1632-40. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS, Etienne-Grimaldi MC, Wei Q. PMID: 21278243; PMCID: PMC3060288.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    430. KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter? Ann Oncol. 2011 Feb; 22(2):484-5. Zhang W, Labonte MJ, Lenz HJ. PMID: 21278223.
      View in: PubMed   Mentions: